{"gene":"SLC25A1","run_date":"2026-04-28T20:42:07","timeline":{"discoveries":[{"year":1993,"finding":"The rat liver mitochondrial tricarboxylate transport protein (SLC25A1 ortholog) was cloned and its primary structure determined. The protein is 298 amino acids (mature form) with a 13-residue presequence, contains three related ~100-amino-acid sequence domains each with two predicted transmembrane α-helices (six total), placing it in the mitochondrial carrier family with a characteristic tripartite topology.","method":"cDNA cloning via PCR with primers from direct protein sequencing; hydrophobicity analysis; Southern blot","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — direct sequencing of purified protein combined with cDNA cloning; foundational structural characterization","pmids":["8514800"],"is_preprint":false},{"year":2009,"finding":"Mutations in the Drosophila ortholog of SLC25A1 (scheggia/sea) impair citrate transport from mitochondria to cytosol, causing extensive chromosome breakage in mitotic cells, ATR-dependent cell cycle arrest, and a dramatic reduction in global histone acetylation. Loss of SLC25A1 by siRNA in human primary fibroblasts similarly leads to chromosome breaks and histone acetylation defects, establishing an evolutionarily conserved role for SLC25A1 in supplying cytosolic citrate (and downstream acetyl-CoA) for chromatin acetylation and genome stability.","method":"Drosophila genetics (sea mutants), siRNA knockdown in human fibroblasts, chromosome breakage assays, ATR pathway analysis, global histone acetylation measurement","journal":"Human molecular genetics","confidence":"High","confidence_rationale":"Tier 2 — orthogonal genetic and biochemical approaches in two organisms with defined cellular phenotypes","pmids":["19654186"],"is_preprint":false},{"year":2011,"finding":"The mitochondrial citrate carrier (CIC/SLC25A1) is induced at the mRNA and protein level by lipopolysaccharide in immune cells. Gene silencing or pharmacological inhibition of CIC significantly reduces production of nitric oxide, reactive oxygen species, and prostaglandins in activated macrophages, demonstrating that CIC-mediated citrate export is required for the generation of inflammatory mediators.","method":"LPS stimulation, CIC gene silencing (siRNA), CIC activity inhibition, NO/ROS/prostaglandin assays","journal":"The Biochemical journal","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal loss-of-function approaches (siRNA and inhibitor) with specific biochemical readouts, replicated across conditions","pmids":["21787310"],"is_preprint":false},{"year":2012,"finding":"SLC25A1 is a member of the mitochondrial carrier superfamily (SLC25) characterized by a tripartite structure, six transmembrane α-helices, and 3-fold repeated signature motifs embedded in the inner mitochondrial membrane. It functions as an antiporter exchanging citrate (and isocitrate) efflux from the mitochondrial matrix for cytosolic malate import.","method":"Comparative sequence analysis, heterologous expression, reconstitution into liposomes, transport assays","journal":"Molecular aspects of medicine","confidence":"High","confidence_rationale":"Tier 1 — reconstitution in liposomes with transport assays; consistent with broader SLC25 family characterization","pmids":["23266187"],"is_preprint":false},{"year":2013,"finding":"Recessive loss-of-function mutations in SLC25A1 cause combined D-2- and L-2-hydroxyglutaric aciduria. Stable isotope labeling experiments in patient fibroblasts demonstrated impaired mitochondrial citrate efflux, and absence of SLC25A1 protein was shown in fibroblasts with certain mutations, establishing that SLC25A1 deficiency is the pathogenic mechanism underlying this neurometabolic disease.","method":"Whole exome sequencing, stable isotope labeling experiments in patient fibroblasts, immunoblotting for SLC25A1 protein","journal":"American journal of human genetics","confidence":"High","confidence_rationale":"Tier 2 — functional impairment demonstrated by isotope labeling in patient cells; 12/12 individuals with this disease had SLC25A1 mutations","pmids":["23561848"],"is_preprint":false},{"year":2014,"finding":"SLC25A1 is transcriptionally induced by TNFα and IFNγ via NF-κB and STAT1 transcription factors. The citrate exported from mitochondria via SLC25A1, and its downstream metabolic intermediate acetyl-CoA, are necessary for cytokine-induced nitric oxide and prostaglandin production, placing SLC25A1-mediated citrate export as a central node in the inflammatory metabolic pathway.","method":"Cytokine stimulation, transcription factor inhibition (NF-κB, STAT1), SLC25A1 knockdown, metabolite measurements (citrate, acetyl-CoA, NO, prostaglandins)","journal":"Biochimica et biophysica acta","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal approaches linking transcriptional regulation to metabolic output with specific pathway placement","pmids":["25072865"],"is_preprint":false},{"year":2014,"finding":"A homozygous missense mutation in SLC25A1 causes impaired neuromuscular junction (NMJ) function in addition to metabolic disease. Mutant SLC25A1 protein showed abnormal carrier function in vitro. Knockdown of SLC25A1 in zebrafish recapitulated the human disease phenotype with clear NMJ abnormalities and axonal outgrowth defects, suggesting the NMJ impairment is related to pre-synaptic nerve terminal defects secondary to mitochondrial citrate transport dysfunction.","method":"Whole exome sequencing, in vitro mutant carrier function assay, zebrafish SLC25A1 knockdown, NMJ morphology analysis","journal":"Journal of neuromuscular diseases","confidence":"Medium","confidence_rationale":"Tier 2 — in vitro functional assay plus zebrafish model; single lab study","pmids":["26870663"],"is_preprint":false},{"year":2014,"finding":"SLC25A1 deficiency (combined D,L-2-hydroxyglutaric aciduria) leads to depletion of cytosolic citrate and accumulation of intramitochondrial citrate. Citrate supplementation (but not malate) in a patient reduced urinary D2HG and L2HG levels and stabilized seizure frequency, consistent with the model that impaired SLC25A1-mediated citrate export drives accumulation of 2-hydroxyglutarate species.","method":"Clinical metabolite monitoring (organic acid profiling), citrate vs. malate treatment intervention in a patient","journal":"Journal of inherited metabolic disease","confidence":"Medium","confidence_rationale":"Tier 3 — single patient clinical intervention providing mechanistic insight; consistent with established transport function","pmids":["24687295"],"is_preprint":false},{"year":2016,"finding":"Severe neonatal SLC25A1 deficiency (homozygous p.Arg198His, within the putative substrate-binding site I of the carrier) results in lactic acidosis, reduced mitochondrial spare respiratory capacity, and increased glycolytic flux in patient fibroblasts, demonstrating that loss of mitochondrial citrate export impairs mitochondrial bioenergetics and forces metabolic reprogramming toward glycolysis.","method":"Exome sequencing, Seahorse respirometry in patient fibroblasts, mitochondrial membrane potential assays, citrate supplementation rescue experiments","journal":"JIMD reports","confidence":"Medium","confidence_rationale":"Tier 2 — functional bioenergetics assays in patient fibroblasts; single case but with multiple orthogonal measurements","pmids":["27306203"],"is_preprint":false},{"year":2018,"finding":"SLC25A1 is upregulated in lung cancer stem cells (CSCs) and by hypoxia/reoxygenation stress and ionizing radiation. SLC25A1 maintains the mitochondrial pool of citrate and redox balance in CSCs; its inhibition (using BTA or CNASB) leads to reactive oxygen species accumulation, reduced mitochondrial metabolism, impaired DNA repair capacity, and inhibition of CSC self-renewal. SLC25A1 inhibition is synthetic lethal with cisplatin or EGFR inhibitor treatment.","method":"SLC25A1 inhibition with BTA/CNASB, CSC sphere assays, ROS measurement, clonogenic survival, xenograft models, metabolic profiling","journal":"Cell death and differentiation","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal functional assays in vitro and in vivo animal models; replicated with two distinct inhibitors","pmids":["29651165"],"is_preprint":false},{"year":2018,"finding":"SLC25A1 upregulation by hypoxia/reoxygenation stress supports cellular and mitochondrial redox homeostasis and metabolic flexibility in cancer cells. Pharmacological inhibition of SLC25A1 disturbs redox balance, lowers mitochondrial metabolism, and radiosensitizes cancer cells by increasing ROS and reducing DNA repair capacity, particularly in chronically hypoxic tumor cells.","method":"SLC25A1 inhibition (BTA, CNASB), irradiation clonogenic assays, ROS measurement, DNA damage (γH2AX) assays, metabolic flux analysis in multiple cancer cell lines","journal":"Frontiers in oncology","confidence":"Medium","confidence_rationale":"Tier 2 — multiple cell lines and inhibitors with mechanistic endpoint measurements; single lab","pmids":["29888201"],"is_preprint":false},{"year":2019,"finding":"ADGRL4/ELTD1 silencing in endothelial cells induces transcriptional upregulation of SLC25A1 (and ACLY), altering the cellular metabolic profile. Affected metabolites include elevated cis-aconitic acid and depleted cytidine monophosphate, suggesting SLC25A1 participates in a metabolic regulatory circuit downstream of ADGRL4/ELTD1 in endothelial cells.","method":"siRNA silencing of ADGRL4/ELTD1 in HUVECs, transcriptional profiling, LC-MS metabolomics","journal":"Metabolites","confidence":"Low","confidence_rationale":"Tier 3 — SLC25A1 upregulation is a downstream consequence; no direct functional manipulation of SLC25A1 itself","pmids":["31775252"],"is_preprint":false},{"year":2020,"finding":"Pharmacological inhibition of Slc25a1 with CTPI-2 in mouse models of NAFLD/NASH reverts steatosis, reduces inflammatory macrophage infiltration, mitigates obesity, and normalizes hyperglycemia. Mechanistically, Slc25a1 inhibition rewires the lipogenic program by blunting PPARγ signaling and inhibiting gluconeogenic gene expression via citrate-dependent activities. Liver-targeted Slc25a1 knockout recapitulates metabolic improvements, demonstrating tissue-specific functions.","method":"CTPI-2 pharmacological inhibition, global Slc25a1 heterozygous knockout, liver-targeted conditional Slc25a1 knockout, high-fat diet NASH model, lipid profiling, glucose tolerance tests, PPARγ and gluconeogenic gene expression analysis","journal":"Cell death and differentiation","confidence":"High","confidence_rationale":"Tier 2 — multiple genetic and pharmacological approaches in vivo with specific mechanistic pathway placement","pmids":["31959914"],"is_preprint":false},{"year":2021,"finding":"SLC25A1 knockdown in colorectal cancer cells inhibits G1/S cell cycle progression and induces apoptosis. SLC25A1 reprograms energy metabolism by: (1) increasing de novo lipid synthesis under normal conditions, and (2) increasing oxidative phosphorylation to protect against energy stress-induced apoptosis, demonstrating dual metabolic roles dependent on nutritional context.","method":"SLC25A1 knockdown and overexpression in CRC cells, cell cycle analysis, apoptosis assays, OXPHOS measurement, de novo lipogenesis assays, xenograft models","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 — bidirectional manipulation (KD and OE) with multiple metabolic readouts; single lab","pmids":["34839347"],"is_preprint":false},{"year":2022,"finding":"Neuronal overexpression of SLC25A1 in mouse forebrain neurons increases steady-state levels of citrate and acetyl-CoA, produces an autistic-like behavioral phenotype with jumping stereotypy, disrupts white matter integrity with activated microglia, and alters synaptic plasticity and morphology. Quantitative acetyl-proteomic analysis reveals differential acetylation adaptations in hippocampus and cortex, linking SLC25A1-mediated citrate export to cytosolic acetyl-CoA availability and downstream protein acetylation in neurons.","method":"Transgenic mouse overexpression of SLC25A1 in forebrain neurons, behavioral testing, metabolomics (citrate, acetyl-CoA), MRI white matter integrity, electrophysiology, quantitative proteomics and acetyl-proteomics","journal":"Brain : a journal of neurology","confidence":"High","confidence_rationale":"Tier 2 — transgenic mouse model with multiple orthogonal biochemical, imaging, behavioral, and proteomic endpoints","pmids":["35203088"],"is_preprint":false},{"year":2022,"finding":"IL-1β stimulation induces translocation of IRAKM Myddosome to mitochondria, where IRAKM interacts with and phosphorylates the mitochondrial citrate carrier Slc25a1. This phosphorylation promotes IL-1β-induced mitochondrial citrate transport to the cytosol and drives de novo lipogenesis in adipocytes. The IRAKM-Slc25a1 axis also mediates IL-1β-induced PGC1α acetylation to regulate thermogenic gene expression. Adipocyte-specific IRAKM deficiency reduces high-fat diet-induced obesity.","method":"Co-immunoprecipitation of IRAKM with Slc25a1, kinase phosphorylation assays, adipocyte-specific IRAKM knockout mice, HFD obesity model, mitochondrial citrate transport assay, de novo lipogenesis measurement, acetylation assays","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1–2 — direct biochemical interaction (Co-IP), kinase assay, and in vivo genetic model with specific metabolic readouts","pmids":["35585086"],"is_preprint":false},{"year":2023,"finding":"KRASG12D upregulates SLC25A1 expression in pancreatic cancer via GLI1, which directly binds the SLC25A1 promoter to stimulate its transcription. Enhanced SLC25A1 expression increases cytosolic citrate, fatty acids, and key lipid metabolism enzymes. A high-fat diet further stimulates the KRASG12D-GLI1-SLC25A1 axis. Pharmacological inhibition of SLC25A1 or GLI1 significantly suppresses pancreatic tumorigenesis in KrasG12D/+ mice.","method":"ChIP demonstrating GLI1 binding to SLC25A1 promoter, genetically engineered KrasG12D mouse models, SLC25A1/GLI1 pharmacological inhibition, metabolomics (citrate, fatty acids), HFD tumor models","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 1–2 — ChIP for direct transcriptional regulation, in vivo mouse model, multiple orthogonal metabolic measurements","pmids":["37695315"],"is_preprint":false},{"year":2023,"finding":"Systemic overexpression of SLC25A1 in mice increases cytosolic citrate and acetyl-CoA but does not engage the ER acetylation machinery (SLC33A1) or cause premature death (unlike SLC13A5 overexpression), revealing that the directionality of citrate import (mitochondrial export via SLC25A1 vs. extracellular import via SLC13A5) produces fundamentally different biological responses and metabolic profiles despite both elevating cytosolic citrate.","method":"Transgenic mice with systemic SLC25A1 overexpression, comparative metabolomics with SLC13A5 transgenic mice, ER acetylation machinery analysis, phenotypic characterization","journal":"Communications biology","confidence":"Medium","confidence_rationale":"Tier 2 — direct comparison of transgenic models with metabolomics; demonstrates source-specific citrate signaling","pmids":["37689798"],"is_preprint":false},{"year":2023,"finding":"SLC25A1 exports citrate from mitochondria to the cytosol, where ATP citrate lyase (ACLY) converts it to acetyl-CoA. This cytosolic acetyl-CoA sustains FSP1 acetylation at K168 (mediated by KAT2B and reversed by HDAC3), preventing FSP1 degradation via K29-linked ubiquitin chains and thus protecting cancer cells from ferroptosis. Pharmacological inhibition of SLC25A1 reduces FSP1 acetylation, promotes its proteasomal degradation, and enhances ferroptosis sensitivity both in vitro and in vivo.","method":"CRISPR-Cas9 screen of SLC superfamily, SLC25A1 inhibition (CTPI-2), ACLY inhibition, FSP1 acetylation and ubiquitination assays, site-directed mutagenesis (K168), KAT2B/HDAC3 identification, ferroptosis assays in vitro and xenograft models","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 1–2 — CRISPR screen, reconstitution of acetylation pathway, mutagenesis of key sites, in vivo validation; multiple orthogonal methods","pmids":["39881208"],"is_preprint":false},{"year":2023,"finding":"Parthenolide (PTL) inhibits SLC25A1 expression, causing ROS production, reduced oxidative phosphorylation, and mitochondrial dysfunction in liver cancer stem cells. SLC25A1 inhibition also decreases IDH2 expression and mitochondrial respiratory chain complex genes. The inhibitory effects of PTL on mitochondrial function and self-renewal are abolished by SLC25A1 knockdown or CTPI-2 treatment, demonstrating that PTL acts through SLC25A1-mediated mitochondrial function.","method":"RNA-seq, SLC25A1 knockdown, CTPI-2 inhibitor, ROS assay, OXPHOS measurement, mitochondrial membrane potential, sphere formation assays, in vivo xenograft","journal":"Cell death discovery","confidence":"Medium","confidence_rationale":"Tier 2 — multiple approaches but PTL has pleiotropic effects; SLC25A1 specificity established by genetic knockdown corroborating inhibitor","pmids":["37741815"],"is_preprint":false}],"current_model":"SLC25A1 (mitochondrial citrate carrier/CIC) is an inner mitochondrial membrane antiporter with a tripartite six-transmembrane-helix structure that exports citrate (and isocitrate) from the mitochondrial matrix in exchange for cytosolic malate; this citrate export fuels cytosolic acetyl-CoA production via ACLY, thereby regulating de novo lipogenesis, histone acetylation and chromatin integrity, ferroptosis resistance (via FSP1 acetylation), inflammatory mediator production (NO, prostaglandins) downstream of NF-κB/STAT1 and IL-1R-IRAKM signaling, cancer stem cell redox balance, and glucose/lipid homeostasis in liver and adipose tissue, while loss-of-function mutations cause combined D,L-2-hydroxyglutaric aciduria with neurometabolic disease."},"narrative":{"teleology":[{"year":1993,"claim":"Cloning the rat liver tricarboxylate carrier established SLC25A1 as a mitochondrial carrier family member with a tripartite six-transmembrane-helix topology, providing the molecular identity needed for all subsequent functional studies.","evidence":"cDNA cloning from direct protein sequencing of purified rat liver carrier; hydrophobicity analysis","pmids":["8514800"],"confidence":"High","gaps":["Human orthologue transport kinetics not yet characterized at this stage","No disease association established"]},{"year":2009,"claim":"Establishing that SLC25A1-mediated citrate export supplies cytosolic acetyl-CoA for histone acetylation answered why a metabolite transporter is essential for genome stability, linking mitochondrial metabolism to chromatin maintenance.","evidence":"Drosophila sea mutant genetics plus siRNA in human fibroblasts; chromosome breakage assays and global histone acetylation measurements","pmids":["19654186"],"confidence":"High","gaps":["Specific histone marks affected not resolved","Whether acetyl-CoA depletion or citrate accumulation is the primary driver of breakage was not distinguished"]},{"year":2011,"claim":"Demonstrating that SLC25A1 is induced by LPS and required for NO, ROS, and prostaglandin production in macrophages established mitochondrial citrate export as a metabolic bottleneck in innate immune activation.","evidence":"siRNA knockdown and pharmacological CIC inhibition in LPS-stimulated macrophages; NO/ROS/prostaglandin quantification","pmids":["21787310"],"confidence":"High","gaps":["Direct metabolic flux measurements of citrate export in immune cells not performed","Relative contribution of citrate versus other mitochondrial metabolites not fully dissected"]},{"year":2012,"claim":"Reconstitution of purified SLC25A1 in liposomes confirmed its identity as a citrate/malate antiporter, providing the biochemical gold standard for its transport mechanism.","evidence":"Heterologous expression, reconstitution into liposomes, direct transport assays","pmids":["23266187"],"confidence":"High","gaps":["High-resolution structural basis of substrate selectivity not yet available","Regulatory post-translational modifications on the carrier not explored"]},{"year":2013,"claim":"Identification of recessive SLC25A1 mutations as the cause of combined D,L-2-hydroxyglutaric aciduria in 12 individuals answered the genetic basis of this neurometabolic disease and confirmed the physiological essentiality of mitochondrial citrate export.","evidence":"Whole-exome sequencing of affected families; stable isotope labeling in patient fibroblasts showing impaired citrate efflux","pmids":["23561848"],"confidence":"High","gaps":["Precise mechanism linking citrate retention to 2-HG accumulation not fully delineated","Genotype–phenotype correlations across different mutations remain incomplete"]},{"year":2014,"claim":"Mapping transcriptional induction of SLC25A1 by TNFα/IFNγ via NF-κB and STAT1 placed the carrier within the inflammatory signaling cascade and identified IRAKM-mediated phosphorylation of SLC25A1 as a direct post-translational activating mechanism during IL-1β signaling in adipocytes.","evidence":"Cytokine stimulation with transcription factor inhibition; Co-IP of IRAKM with SLC25A1, kinase assays, adipocyte-specific knockout mice","pmids":["25072865","35585086"],"confidence":"High","gaps":["Specific phosphorylation sites on SLC25A1 and their individual functional consequences not fully mapped","Whether phosphorylation alters transport kinetics or carrier stability not distinguished"]},{"year":2014,"claim":"Demonstrating NMJ defects in a patient with a homozygous SLC25A1 missense mutation and recapitulation in zebrafish knockdown expanded the disease phenotype beyond metabolic aciduria to include neuromuscular dysfunction.","evidence":"Patient exome sequencing, in vitro carrier function assay, zebrafish morpholino knockdown with NMJ morphology analysis","pmids":["26870663"],"confidence":"Medium","gaps":["Whether NMJ defect is a direct consequence of local citrate depletion or secondary to systemic metabolic imbalance is unclear","Single-family study"]},{"year":2018,"claim":"Showing that SLC25A1 is upregulated in cancer stem cells and required for their redox balance, DNA repair, and self-renewal established SLC25A1 as a therapeutic vulnerability, with pharmacological inhibition being synthetic lethal with cisplatin or EGFR blockade.","evidence":"BTA and CNASB inhibitors in lung CSC sphere assays, ROS measurement, clonogenic survival, xenograft models","pmids":["29651165","29888201"],"confidence":"High","gaps":["Specificity of BTA/CNASB for SLC25A1 versus other mitochondrial carriers not fully established","Patient-derived tumor responses not tested"]},{"year":2020,"claim":"Pharmacological and liver-specific genetic ablation of SLC25A1 in NAFLD/NASH mouse models reversed steatosis, obesity, and hyperglycemia by blunting PPARγ-driven lipogenesis and gluconeogenesis, demonstrating tissue-level metabolic functions.","evidence":"CTPI-2 treatment, global heterozygous and liver-conditional Slc25a1 knockout mice on high-fat diet; lipid profiling, glucose tolerance tests","pmids":["31959914"],"confidence":"High","gaps":["Long-term safety of SLC25A1 inhibition in liver not assessed","Compensatory metabolic pathways upon chronic inhibition not characterized"]},{"year":2022,"claim":"Neuronal overexpression of SLC25A1 produced autistic-like behaviors, white matter disruption, and altered synaptic plasticity in mice, with acetyl-proteomics revealing region-specific protein acetylation changes, directly demonstrating that excess mitochondrial citrate export reprograms the neuronal acetylome.","evidence":"Forebrain-specific SLC25A1 transgenic mice; behavioral testing, MRI, electrophysiology, quantitative acetyl-proteomics","pmids":["35203088"],"confidence":"High","gaps":["Causal link between specific acetylation targets and behavioral phenotype not established","Reversibility of phenotype upon SLC25A1 normalization not tested"]},{"year":2023,"claim":"Identification of the KRAS–GLI1–SLC25A1 transcriptional axis in pancreatic cancer revealed how oncogenic signaling co-opts mitochondrial citrate export to fuel lipogenesis and tumorigenesis, and showed that GLI1 directly binds the SLC25A1 promoter.","evidence":"ChIP for GLI1 at SLC25A1 promoter, KrasG12D mouse models, pharmacological SLC25A1/GLI1 inhibition, high-fat diet tumor studies","pmids":["37695315"],"confidence":"High","gaps":["Whether GLI1-dependent regulation occurs in non-pancreatic KRAS-driven cancers not tested","Relative contribution of SLC25A1 versus other lipogenic enzymes to KRAS-driven tumor growth not quantified"]},{"year":2023,"claim":"Delineation of the SLC25A1→ACLY→acetyl-CoA→KAT2B→FSP1-K168-acetylation pathway established a direct mechanism by which mitochondrial citrate export protects cells from ferroptosis by preventing ubiquitin-dependent FSP1 degradation.","evidence":"CRISPR screen of SLC superfamily, CTPI-2 and ACLY inhibitors, FSP1 K168 mutagenesis, KAT2B/HDAC3 identification, in vivo ferroptosis assays","pmids":["39881208"],"confidence":"High","gaps":["Whether this ferroptosis-protective mechanism operates in non-cancer cell types is unknown","Structural basis for KAT2B specificity toward FSP1-K168 not determined"]},{"year":null,"claim":"A high-resolution structure of human SLC25A1 in distinct conformational states, the full catalog of regulatory phosphorylation sites and their kinases, and the in vivo therapeutic index of SLC25A1 inhibition in cancer and metabolic disease remain to be established.","evidence":"","pmids":[],"confidence":"Low","gaps":["No atomic-resolution structure of human SLC25A1 reported","Complete post-translational modification map (phosphorylation, acetylation) and their transport-kinetic consequences lacking","Clinical translatability of SLC25A1 inhibitors not assessed in human trials"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0005215","term_label":"transporter activity","supporting_discovery_ids":[0,3,4]},{"term_id":"GO:0140104","term_label":"molecular carrier activity","supporting_discovery_ids":[3,4]}],"localization":[{"term_id":"GO:0005739","term_label":"mitochondrion","supporting_discovery_ids":[0,3,4,8,15]}],"pathway":[{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[1,3,5,12,13,16,18]},{"term_id":"R-HSA-382551","term_label":"Transport of small molecules","supporting_discovery_ids":[0,3,4,7,8]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[2,5]},{"term_id":"R-HSA-4839726","term_label":"Chromatin organization","supporting_discovery_ids":[1,14]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[13,18]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[4,6,9,16]}],"complexes":[],"partners":["ACLY","IRAKM","GLI1","FSP1","KAT2B","HDAC3"],"other_free_text":[]},"mechanistic_narrative":"SLC25A1 is an inner mitochondrial membrane antiporter that exports citrate (and isocitrate) from the mitochondrial matrix in exchange for cytosolic malate, thereby serving as the principal conduit for mitochondrial citrate to reach the cytoplasm where ATP citrate lyase (ACLY) converts it to acetyl-CoA [PMID:8514800, PMID:23266187]. This citrate-to-acetyl-CoA axis supplies substrate for de novo lipogenesis, histone and protein acetylation critical for chromatin integrity and genome stability, and inflammatory mediator synthesis (NO, prostaglandins) downstream of NF-κB/STAT1 signaling in activated macrophages [PMID:19654186, PMID:21787310, PMID:25072865]. SLC25A1-derived acetyl-CoA also sustains FSP1 acetylation to protect cells from ferroptosis, maintains redox homeostasis in cancer stem cells, and is regulated by IRAKM-dependent phosphorylation during IL-1β-driven lipogenesis in adipocytes and by KRAS–GLI1 transcriptional activation in pancreatic cancer [PMID:39881208, PMID:29651165, PMID:35585086, PMID:37695315]. Recessive loss-of-function mutations in SLC25A1 cause combined D,L-2-hydroxyglutaric aciduria, a neurometabolic disorder characterized by impaired mitochondrial citrate efflux, 2-hydroxyglutarate accumulation, and neuromuscular dysfunction [PMID:23561848, PMID:26870663]."},"prefetch_data":{"uniprot":{"accession":"P53007","full_name":"Tricarboxylate transport protein, mitochondrial","aliases":["Citrate transport protein","CTP","Mitochondrial citrate carrier","CIC","Solute carrier family 25 member 1","Tricarboxylate carrier protein"],"length_aa":311,"mass_kda":34.0,"function":"Mitochondrial electroneutral antiporter that exports citrate from the mitochondria into the cytosol in exchange for malate (PubMed:26870663, PubMed:29031613, PubMed:29238895, PubMed:39881208, PubMed:38937634). Also able to mediate the exchange of citrate for isocitrate, phosphoenolpyruvate, cis-aconitate and to a lesser extent trans-aconitate, maleate and succinate (PubMed:29031613). Substrate exchange across the membrane occurs consecutively with one substrate being transported first, then dissociating from the substrate binding site before the second substrate binds for transport in the opposite direction (PubMed:38937634). In the cytoplasm, citrate plays important roles in fatty acid and sterol synthesis, regulation of glycolysis, protein acetylation, and other physiopathological processes (PubMed:29031613, PubMed:29238895, PubMed:39881208)","subcellular_location":"Mitochondrion inner membrane","url":"https://www.uniprot.org/uniprotkb/P53007/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/SLC25A1","classification":"Not Classified","n_dependent_lines":192,"n_total_lines":1208,"dependency_fraction":0.15894039735099338},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/SLC25A1","total_profiled":1310},"omim":[{"mim_id":"618197","title":"MYASTHENIC SYNDROME, CONGENITAL, 23, PRESYNAPTIC; CMS23","url":"https://www.omim.org/entry/618197"},{"mim_id":"615182","title":"COMBINED D-2- AND L-2-HYDROXYGLUTARIC ACIDURIA; D2L2AD","url":"https://www.omim.org/entry/615182"},{"mim_id":"601462","title":"MYASTHENIC SYNDROME, CONGENITAL, 1A, SLOW-CHANNEL; CMS1A","url":"https://www.omim.org/entry/601462"},{"mim_id":"300212","title":"REGUCALCIN; RGN","url":"https://www.omim.org/entry/300212"},{"mim_id":"192430","title":"VELOCARDIOFACIAL SYNDROME; VCFS","url":"https://www.omim.org/entry/192430"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"liver","ntpm":206.9}],"url":"https://www.proteinatlas.org/search/SLC25A1"},"hgnc":{"alias_symbol":["CTP","CIC"],"prev_symbol":["SLC20A3"]},"alphafold":{"accession":"P53007","domains":[{"cath_id":"-","chopping":"186-278","consensus_level":"medium","plddt":78.7845,"start":186,"end":278}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P53007","model_url":"https://alphafold.ebi.ac.uk/files/AF-P53007-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P53007-F1-predicted_aligned_error_v6.png","plddt_mean":74.69},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=SLC25A1","jax_strain_url":"https://www.jax.org/strain/search?query=SLC25A1"},"sequence":{"accession":"P53007","fasta_url":"https://rest.uniprot.org/uniprotkb/P53007.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P53007/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P53007"}},"corpus_meta":[{"pmid":"22869205","id":"PMC_22869205","title":"Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas.","date":"2012","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/22869205","citation_count":462,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21817013","id":"PMC_21817013","title":"Mutations in CIC and FUBP1 contribute to human oligodendroglioma.","date":"2011","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/21817013","citation_count":420,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7845466","id":"PMC_7845466","title":"Gating of the voltage-dependent chloride channel CIC-0 by the permeant anion.","date":"1995","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/7845466","citation_count":298,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9370319","id":"PMC_9370319","title":"CTP:phosphocholine cytidylyltransferase.","date":"1997","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/9370319","citation_count":186,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10973058","id":"PMC_10973058","title":"Regulation of CTP:phosphocholine cytidylyltransferase by amphitropism and relocalization.","date":"2000","source":"Trends in biochemical sciences","url":"https://pubmed.ncbi.nlm.nih.gov/10973058","citation_count":172,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25072865","id":"PMC_25072865","title":"A key role of the mitochondrial citrate carrier (SLC25A1) in TNFα- and IFNγ-triggered inflammation.","date":"2014","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/25072865","citation_count":163,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26685084","id":"PMC_26685084","title":"CIC-rearranged Sarcomas: A Study of 20 Cases and Comparisons With Ewing Sarcomas.","date":"2016","source":"The American journal of surgical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/26685084","citation_count":160,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31835030","id":"PMC_31835030","title":"ParB-type DNA Segregation Proteins Are CTP-Dependent Molecular Switches.","date":"2019","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/31835030","citation_count":126,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22588899","id":"PMC_22588899","title":"CIC and FUBP1 mutations in oligodendrogliomas, oligoastrocytomas and astrocytomas.","date":"2012","source":"Acta neuropathologica","url":"https://pubmed.ncbi.nlm.nih.gov/22588899","citation_count":115,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26165797","id":"PMC_26165797","title":"CTP:phosphocholine cytidylyltransferase: Function, regulation, and structure of an amphitropic enzyme required for membrane biogenesis.","date":"2015","source":"Progress in lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/26165797","citation_count":115,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23561848","id":"PMC_23561848","title":"Deficiency in SLC25A1, encoding the mitochondrial citrate carrier, causes combined D-2- and L-2-hydroxyglutaric aciduria.","date":"2013","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/23561848","citation_count":114,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29651165","id":"PMC_29651165","title":"The mitochondrial citrate carrier, SLC25A1, drives stemness and therapy resistance in non-small cell lung cancer.","date":"2018","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/29651165","citation_count":112,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31649139","id":"PMC_31649139","title":"Self-organization of parS centromeres by the ParB CTP hydrolase.","date":"2019","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/31649139","citation_count":105,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31959914","id":"PMC_31959914","title":"Inhibition of the mitochondrial citrate carrier, Slc25a1, reverts steatosis, glucose intolerance, and inflammation in preclinical models of NAFLD/NASH.","date":"2020","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/31959914","citation_count":98,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28178529","id":"PMC_28178529","title":"ATXN1L, CIC, and ETS Transcription Factors Modulate Sensitivity to MAPK Pathway Inhibition.","date":"2017","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/28178529","citation_count":96,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28404587","id":"PMC_28404587","title":"CIC-DUX4 Induces Small Round Cell Sarcomas Distinct from Ewing Sarcoma.","date":"2017","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/28404587","citation_count":92,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17325045","id":"PMC_17325045","title":"Developmental and metabolic effects of disruption of the mouse CTP:phosphoethanolamine cytidylyltransferase gene (Pcyt2).","date":"2007","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/17325045","citation_count":92,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18458076","id":"PMC_18458076","title":"Characterization of the yeast DGK1-encoded CTP-dependent diacylglycerol kinase.","date":"2008","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18458076","citation_count":81,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24947144","id":"PMC_24947144","title":"CIC-DUX sarcomas demonstrate frequent MYC amplification and ETS-family transcription factor expression.","date":"2014","source":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","url":"https://pubmed.ncbi.nlm.nih.gov/24947144","citation_count":78,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24920825","id":"PMC_24920825","title":"Common regulatory control of CTP synthase enzyme activity and filament formation.","date":"2014","source":"Molecular biology of the cell","url":"https://pubmed.ncbi.nlm.nih.gov/24920825","citation_count":78,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2536019","id":"PMC_2536019","title":"CTP:phosphocholine cytidylyltransferase is a substrate for cAMP-dependent protein kinase in vitro.","date":"1989","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/2536019","citation_count":74,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24503052","id":"PMC_24503052","title":"CTP synthase forms cytoophidia in the cytoplasm and nucleus.","date":"2014","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/24503052","citation_count":73,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17189343","id":"PMC_17189343","title":"Defects in CTP:PHOSPHORYLETHANOLAMINE CYTIDYLYLTRANSFERASE affect embryonic and postembryonic development in Arabidopsis.","date":"2006","source":"The Plant cell","url":"https://pubmed.ncbi.nlm.nih.gov/17189343","citation_count":70,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26870663","id":"PMC_26870663","title":"Mutations in the Mitochondrial Citrate Carrier SLC25A1 are Associated with Impaired Neuromuscular Transmission.","date":"2014","source":"Journal of neuromuscular diseases","url":"https://pubmed.ncbi.nlm.nih.gov/26870663","citation_count":69,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28493604","id":"PMC_28493604","title":"CIC break-apart fluorescence in-situ hybridization misses a subset of CIC-DUX4 sarcomas: a clinicopathological and molecular study.","date":"2017","source":"Histopathology","url":"https://pubmed.ncbi.nlm.nih.gov/28493604","citation_count":67,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29888201","id":"PMC_29888201","title":"The Mitochondrial Citrate Carrier (SLC25A1) Sustains Redox Homeostasis and Mitochondrial Metabolism Supporting Radioresistance of Cancer Cells With Tolerance to Cycling Severe Hypoxia.","date":"2018","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/29888201","citation_count":65,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25223282","id":"PMC_25223282","title":"Ack kinase regulates CTP synthase filaments during Drosophila oogenesis.","date":"2014","source":"EMBO reports","url":"https://pubmed.ncbi.nlm.nih.gov/25223282","citation_count":64,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26889675","id":"PMC_26889675","title":"The Interplay between Myc and CTP Synthase in Drosophila.","date":"2016","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/26889675","citation_count":63,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8393871","id":"PMC_8393871","title":"Expression, purification, and characterization of CTP:glycerol-3-phosphate cytidylyltransferase from Bacillus subtilis.","date":"1993","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8393871","citation_count":63,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28188754","id":"PMC_28188754","title":"NUTM2A-CIC fusion small round cell sarcoma: a genetically distinct variant of CIC-rearranged sarcoma.","date":"2017","source":"Human pathology","url":"https://pubmed.ncbi.nlm.nih.gov/28188754","citation_count":63,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29844126","id":"PMC_29844126","title":"The Tumor Suppressor CIC Directly Regulates MAPK Pathway Genes via Histone Deacetylation.","date":"2018","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/29844126","citation_count":59,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31329165","id":"PMC_31329165","title":"CIC-DUX4 oncoprotein drives sarcoma metastasis and tumorigenesis via distinct regulatory programs.","date":"2019","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/31329165","citation_count":56,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8982874","id":"PMC_8982874","title":"Isolation and characterization of ECT1 gene encoding CTP: phosphoethanolamine cytidylyltransferase of Saccharomyces cerevisiae.","date":"1996","source":"Journal of biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8982874","citation_count":56,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21920316","id":"PMC_21920316","title":"An ana2/ctp/mud complex regulates spindle orientation in Drosophila neuroblasts.","date":"2011","source":"Developmental cell","url":"https://pubmed.ncbi.nlm.nih.gov/21920316","citation_count":56,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7797479","id":"PMC_7797479","title":"Phosphorylation of CTP synthetase from Saccharomyces cerevisiae by protein kinase C.","date":"1995","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/7797479","citation_count":55,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10208837","id":"PMC_10208837","title":"CTP:phosphocholine cytidylyltransferase: insights into regulatory mechanisms and novel functions.","date":"1999","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/10208837","citation_count":54,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28680140","id":"PMC_28680140","title":"Generation of novel patient-derived CIC- DUX4 sarcoma xenografts and cell lines.","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/28680140","citation_count":53,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19654186","id":"PMC_19654186","title":"A conserved role for the mitochondrial citrate transporter Sea/SLC25A1 in the maintenance of chromosome integrity.","date":"2009","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19654186","citation_count":52,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23459760","id":"PMC_23459760","title":"Only one isoform of Drosophila melanogaster CTP synthase forms the cytoophidium.","date":"2013","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/23459760","citation_count":50,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34839347","id":"PMC_34839347","title":"SLC25A1 promotes tumor growth and survival by reprogramming energy metabolism in colorectal cancer.","date":"2021","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/34839347","citation_count":49,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24030748","id":"PMC_24030748","title":"Loss of CIC and FUBP1 expressions are potential markers of shorter time to recurrence in oligodendroglial tumors.","date":"2013","source":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","url":"https://pubmed.ncbi.nlm.nih.gov/24030748","citation_count":48,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"334776","id":"PMC_334776","title":"Asymmetry of binding and physical assignments of CTP and ATP sites in aspartate transcarbamoylase.","date":"1977","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/334776","citation_count":48,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31902586","id":"PMC_31902586","title":"Drosophila CTP synthase can form distinct substrate- and product-bound filaments.","date":"2019","source":"Journal of genetics and genomics = Yi chuan xue bao","url":"https://pubmed.ncbi.nlm.nih.gov/31902586","citation_count":47,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34613769","id":"PMC_34613769","title":"Relief of ParB autoinhibition by parS DNA catalysis and recycling of ParB by CTP hydrolysis promote bacterial centromere assembly.","date":"2021","source":"Science advances","url":"https://pubmed.ncbi.nlm.nih.gov/34613769","citation_count":46,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34250901","id":"PMC_34250901","title":"CTP promotes efficient ParB-dependent DNA condensation by facilitating one-dimensional diffusion from parS.","date":"2021","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/34250901","citation_count":45,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30030857","id":"PMC_30030857","title":"Characterization of filament-forming CTP synthases from Arabidopsis thaliana.","date":"2018","source":"The Plant journal : for cell and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/30030857","citation_count":45,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8626655","id":"PMC_8626655","title":"Regulation of yeast CTP synthetase activity by protein kinase C.","date":"1996","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8626655","citation_count":45,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26545048","id":"PMC_26545048","title":"Molecular background of oligodendroglioma: 1p/19q, IDH, TERT, CIC and FUBP1.","date":"2015","source":"CNS oncology","url":"https://pubmed.ncbi.nlm.nih.gov/26545048","citation_count":44,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34397383","id":"PMC_34397383","title":"A CTP-dependent gating mechanism enables ParB spreading on DNA.","date":"2021","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/34397383","citation_count":43,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8075080","id":"PMC_8075080","title":"Purification and characterization of CTP synthetase, the product of the URA7 gene in Saccharomyces cerevisiae.","date":"1994","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8075080","citation_count":43,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27306060","id":"PMC_27306060","title":"Ewing sarcoma and the new emerging Ewing-like sarcomas: (CIC and BCOR-rearranged-sarcomas). A systematic review.","date":"2016","source":"Histology and histopathology","url":"https://pubmed.ncbi.nlm.nih.gov/27306060","citation_count":42,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7918629","id":"PMC_7918629","title":"Primary structure and expression of a human CTP:phosphocholine cytidylyltransferase.","date":"1994","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/7918629","citation_count":42,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26482795","id":"PMC_26482795","title":"Regulation of CTP Synthase Filament Formation During DNA Endoreplication in Drosophila.","date":"2015","source":"Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/26482795","citation_count":41,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12928431","id":"PMC_12928431","title":"Enhanced expression and activation of CTP:phosphocholine cytidylyltransferase beta2 during neurite outgrowth.","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12928431","citation_count":40,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34902429","id":"PMC_34902429","title":"CTP-controlled liquid-liquid phase separation of ParB.","date":"2021","source":"Journal of molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/34902429","citation_count":40,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11483628","id":"PMC_11483628","title":"CTP:phosphocholine cytidylyltransferase, a new sterol- and SREBP-responsive gene.","date":"2001","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/11483628","citation_count":36,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15981098","id":"PMC_15981098","title":"CIC, a gene involved in cerebellar development and ErbB signaling, is significantly expressed in medulloblastomas.","date":"2005","source":"Journal of neuro-oncology","url":"https://pubmed.ncbi.nlm.nih.gov/15981098","citation_count":36,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36788092","id":"PMC_36788092","title":"Expanding the Molecular Diversity of CIC-Rearranged Sarcomas With Novel and Very Rare Partners.","date":"2023","source":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","url":"https://pubmed.ncbi.nlm.nih.gov/36788092","citation_count":35,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26357005","id":"PMC_26357005","title":"ETV/Pea3 family transcription factor-encoding genes are overexpressed in CIC-mutant oligodendrogliomas.","date":"2015","source":"Genes, chromosomes & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/26357005","citation_count":34,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10393561","id":"PMC_10393561","title":"Identification of Ser424 as the protein kinase A phosphorylation site in CTP synthetase from Saccharomyces cerevisiae.","date":"1999","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10393561","citation_count":34,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30184506","id":"PMC_30184506","title":"Histidine-Dependent Protein Methylation Is Required for Compartmentalization of CTP Synthase.","date":"2018","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/30184506","citation_count":33,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31870501","id":"PMC_31870501","title":"Undifferentiated round cell sarcomas with CIC-DUX4 gene fusion: expanding the clinical spectrum.","date":"2019","source":"Pathology","url":"https://pubmed.ncbi.nlm.nih.gov/31870501","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30093628","id":"PMC_30093628","title":"Transcriptomic analysis of CIC and ATXN1L reveal a functional relationship exploited by cancer.","date":"2018","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/30093628","citation_count":30,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17804406","id":"PMC_17804406","title":"Calmodulin binds and stabilizes the regulatory enzyme, CTP: phosphocholine cytidylyltransferase.","date":"2007","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17804406","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"6089904","id":"PMC_6089904","title":"Trifluoperazine and chlorpromazine inhibit phosphatidylcholine biosynthesis and CTP:phosphocholine cytidylyltransferase in HeLa cells.","date":"1984","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/6089904","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9370320","id":"PMC_9370320","title":"CTP:phosphoethanolamine cytidylyltransferase.","date":"1997","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/9370320","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34270916","id":"PMC_34270916","title":"CTP regulates membrane-binding activity of the nucleoid occlusion protein Noc.","date":"2021","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/34270916","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32155762","id":"PMC_32155762","title":"DNA Methylation Profiling for Diagnosing Undifferentiated Sarcoma with Capicua Transcriptional Receptor (CIC) Alterations.","date":"2020","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/32155762","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24687295","id":"PMC_24687295","title":"Combined D2-/L2-hydroxyglutaric aciduria (SLC25A1 deficiency): clinical course and effects of citrate treatment.","date":"2014","source":"Journal of inherited metabolic disease","url":"https://pubmed.ncbi.nlm.nih.gov/24687295","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32676453","id":"PMC_32676453","title":"Radiomics Features Predict CIC Mutation Status in Lower Grade Glioma.","date":"2020","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/32676453","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37695315","id":"PMC_37695315","title":"Oncogenic KRASG12D Reprograms Lipid Metabolism by Upregulating SLC25A1 to Drive Pancreatic Tumorigenesis.","date":"2023","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/37695315","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15713672","id":"PMC_15713672","title":"Interdomain and membrane interactions of CTP:phosphocholine cytidylyltransferase revealed via limited proteolysis and mass spectrometry.","date":"2005","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15713672","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35440765","id":"PMC_35440765","title":"Co-expression of ERG and CD31 in a subset of CIC-rearranged sarcoma: a potential diagnostic pitfall.","date":"2022","source":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","url":"https://pubmed.ncbi.nlm.nih.gov/35440765","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32073140","id":"PMC_32073140","title":"Making heads or tails - the emergence of capicua (CIC) as an important multifunctional tumour suppressor.","date":"2020","source":"The Journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/32073140","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37741815","id":"PMC_37741815","title":"A novel SLC25A1 inhibitor, parthenolide, suppresses the growth and stemness of liver cancer stem cells with metabolic vulnerability.","date":"2023","source":"Cell death discovery","url":"https://pubmed.ncbi.nlm.nih.gov/37741815","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2164421","id":"PMC_2164421","title":"CTP:phosphocholine cytidylyltransferase in rat lung: relationship between cytosolic and membrane forms.","date":"1990","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/2164421","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11404253","id":"PMC_11404253","title":"CTP:phosphocholine cytidylyltransferase inhibition by ceramide via PKC-alpha, p38 MAPK, cPLA2, and 5-lipoxygenase.","date":"2001","source":"American journal of physiology. Lung cellular and molecular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/11404253","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31775252","id":"PMC_31775252","title":"ADGRL4/ELTD1 Silencing in Endothelial Cells Induces ACLY and SLC25A1 and Alters the Cellular Metabolic Profile.","date":"2019","source":"Metabolites","url":"https://pubmed.ncbi.nlm.nih.gov/31775252","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8951811","id":"PMC_8951811","title":"Chlamydia trachomatis CTP synthetase: molecular characterization and developmental regulation of expression.","date":"1996","source":"Molecular microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/8951811","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20427062","id":"PMC_20427062","title":"Complementation of the metabolic defect in CTP:phosphoethanolamine cytidylyltransferase (Pcyt2)-deficient primary hepatocytes.","date":"2010","source":"Metabolism: clinical and experimental","url":"https://pubmed.ncbi.nlm.nih.gov/20427062","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"39881208","id":"PMC_39881208","title":"SLC25A1 and ACLY maintain cytosolic acetyl-CoA and regulate ferroptosis susceptibility via FSP1 acetylation.","date":"2025","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/39881208","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35859319","id":"PMC_35859319","title":"A case of CIC-rearranged sarcoma with CIC-LEUTX gene fusion in spinal cord.","date":"2022","source":"Neuropathology : official journal of the Japanese Society of Neuropathology","url":"https://pubmed.ncbi.nlm.nih.gov/35859319","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32814170","id":"PMC_32814170","title":"Advances into Understanding the Vital Role of the Mitochondrial Citrate Carrier (CIC) in Metabolic Diseases.","date":"2020","source":"Pharmacological research","url":"https://pubmed.ncbi.nlm.nih.gov/32814170","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10493918","id":"PMC_10493918","title":"Cloning and expression of CTP:phosphoethanolamine cytidylyltransferase cDNA from rat liver.","date":"1999","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/10493918","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28342900","id":"PMC_28342900","title":"Critical roles of CTP synthase N-terminal in cytoophidium assembly.","date":"2017","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/28342900","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36647117","id":"PMC_36647117","title":"CIC reduces xCT/SLC7A11 expression and glutamate release in glioma.","date":"2023","source":"Acta neuropathologica communications","url":"https://pubmed.ncbi.nlm.nih.gov/36647117","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37348953","id":"PMC_37348953","title":"Differential roles of CTP synthetases CTPS1 and CTPS2 in cell proliferation.","date":"2023","source":"Life science alliance","url":"https://pubmed.ncbi.nlm.nih.gov/37348953","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27306203","id":"PMC_27306203","title":"Severe Neonatal Presentation of Mitochondrial Citrate Carrier (SLC25A1) Deficiency.","date":"2016","source":"JIMD reports","url":"https://pubmed.ncbi.nlm.nih.gov/27306203","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36871427","id":"PMC_36871427","title":"CTP switches in ParABS-mediated bacterial chromosome segregation and beyond.","date":"2023","source":"Current opinion in microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/36871427","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35203088","id":"PMC_35203088","title":"Increased expression of SLC25A1/CIC causes an autistic-like phenotype with altered neuron morphology.","date":"2022","source":"Brain : a journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/35203088","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34685592","id":"PMC_34685592","title":"The CAM Model for CIC-DUX4 Sarcoma and Its Potential Use for Precision Medicine.","date":"2021","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/34685592","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22764088","id":"PMC_22764088","title":"Mechanism of hypertriglyceridemia in CTP:phosphoethanolamine cytidylyltransferase-deficient mice.","date":"2012","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/22764088","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15147238","id":"PMC_15147238","title":"Membrane lipid biosynthesis in Chlamydomonas reinhardtii: expression and characterization of CTP:phosphoethanolamine cytidylyltransferase.","date":"2004","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/15147238","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35715887","id":"PMC_35715887","title":"Central nervous system sarcoma with ATXN1::DUX4 fusion expands the concept of CIC-rearranged sarcoma.","date":"2022","source":"Genes, chromosomes & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/35715887","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35585086","id":"PMC_35585086","title":"IL-1R-IRAKM-Slc25a1 signaling axis reprograms lipogenesis in adipocytes to promote diet-induced obesity in mice.","date":"2022","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/35585086","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32234309","id":"PMC_32234309","title":"Membrane Lipids Assist Catalysis by CTP: Phosphocholine Cytidylyltransferase.","date":"2020","source":"Journal of molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/32234309","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35315355","id":"PMC_35315355","title":"WEE1 kinase is a therapeutic vulnerability in CIC-DUX4 undifferentiated sarcoma.","date":"2022","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/35315355","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35093696","id":"PMC_35093696","title":"CIC rearranged sarcomas: A single institution experience of the potential pitfalls in interpreting CIC FISH results.","date":"2022","source":"Pathology, research and practice","url":"https://pubmed.ncbi.nlm.nih.gov/35093696","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9510335","id":"PMC_9510335","title":"Enzymatic incorporation of 2'-thio-CTP into the HDV ribozyme.","date":"1998","source":"RNA (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/9510335","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37689798","id":"PMC_37689798","title":"The citrate transporters SLC13A5 and SLC25A1 elicit different metabolic responses and phenotypes in the mouse.","date":"2023","source":"Communications biology","url":"https://pubmed.ncbi.nlm.nih.gov/37689798","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12477932","id":"PMC_12477932","title":"Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12477932","citation_count":1479,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26496610","id":"PMC_26496610","title":"A human interactome in three quantitative dimensions organized by stoichiometries and abundances.","date":"2015","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/26496610","citation_count":1015,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"29507755","id":"PMC_29507755","title":"VIRMA mediates preferential m6A mRNA methylation in 3'UTR and near stop codon and associates with alternative polyadenylation.","date":"2018","source":"Cell discovery","url":"https://pubmed.ncbi.nlm.nih.gov/29507755","citation_count":829,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"17353931","id":"PMC_17353931","title":"Large-scale mapping of human protein-protein interactions by mass spectrometry.","date":"2007","source":"Molecular systems biology","url":"https://pubmed.ncbi.nlm.nih.gov/17353931","citation_count":733,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"22939629","id":"PMC_22939629","title":"A census of human soluble protein complexes.","date":"2012","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/22939629","citation_count":689,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21873635","id":"PMC_21873635","title":"Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium.","date":"2011","source":"Briefings in bioinformatics","url":"https://pubmed.ncbi.nlm.nih.gov/21873635","citation_count":656,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19056867","id":"PMC_19056867","title":"Large-scale proteomics and phosphoproteomics of urinary exosomes.","date":"2008","source":"Journal of the American Society of Nephrology : JASN","url":"https://pubmed.ncbi.nlm.nih.gov/19056867","citation_count":607,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"30022168","id":"PMC_30022168","title":"The shieldin complex mediates 53BP1-dependent DNA repair.","date":"2018","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/30022168","citation_count":502,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"23266187","id":"PMC_23266187","title":"The mitochondrial transporter family SLC25: identification, properties and physiopathology.","date":"2012","source":"Molecular aspects of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/23266187","citation_count":492,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15489334","id":"PMC_15489334","title":"The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).","date":"2004","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/15489334","citation_count":438,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"22286219","id":"PMC_22286219","title":"Genome-wide association study identifies multiple loci influencing human serum metabolite levels.","date":"2012","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/22286219","citation_count":436,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26344197","id":"PMC_26344197","title":"Panorama of ancient metazoan macromolecular complexes.","date":"2015","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/26344197","citation_count":407,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8889548","id":"PMC_8889548","title":"Normalization and subtraction: two approaches to facilitate gene discovery.","date":"1996","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/8889548","citation_count":401,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"29656893","id":"PMC_29656893","title":"DNA Repair Network Analysis Reveals Shieldin as a Key Regulator of NHEJ and PARP Inhibitor Sensitivity.","date":"2018","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/29656893","citation_count":379,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"34079125","id":"PMC_34079125","title":"A proximity-dependent biotinylation map of a human cell.","date":"2021","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/34079125","citation_count":339,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21787310","id":"PMC_21787310","title":"The mitochondrial citrate carrier: a new player in inflammation.","date":"2011","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/21787310","citation_count":311,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"27342126","id":"PMC_27342126","title":"Identification of Zika Virus and Dengue Virus Dependency Factors using Functional Genomics.","date":"2016","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/27342126","citation_count":306,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19167051","id":"PMC_19167051","title":"Importin 8 is a gene silencing factor that targets argonaute proteins to distinct mRNAs.","date":"2009","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/19167051","citation_count":281,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"34800366","id":"PMC_34800366","title":"Quantitative high-confidence human mitochondrial proteome and its dynamics in cellular context.","date":"2021","source":"Cell metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/34800366","citation_count":239,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8944226","id":"PMC_8944226","title":"Biosynthesis of triacylglycerols.","date":"1996","source":"Progress in lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/8944226","citation_count":231,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"27499296","id":"PMC_27499296","title":"Mitochondrial Protein Interaction Mapping Identifies Regulators of Respiratory Chain Function.","date":"2016","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/27499296","citation_count":220,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19738201","id":"PMC_19738201","title":"Proteomic analysis of integrin-associated complexes identifies RCC2 as a dual regulator of Rac1 and Arf6.","date":"2009","source":"Science signaling","url":"https://pubmed.ncbi.nlm.nih.gov/19738201","citation_count":207,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"29568061","id":"PMC_29568061","title":"An AP-MS- and BioID-compatible MAC-tag enables comprehensive mapping of protein interactions and subcellular localizations.","date":"2018","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/29568061","citation_count":201,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"28685749","id":"PMC_28685749","title":"The E3 ubiquitin ligase and RNA-binding protein ZNF598 orchestrates ribosome quality control of premature polyadenylated mRNAs.","date":"2017","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/28685749","citation_count":176,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"32807901","id":"PMC_32807901","title":"UFMylation maintains tumour suppressor p53 stability by antagonizing its ubiquitination.","date":"2020","source":"Nature cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/32807901","citation_count":168,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19240061","id":"PMC_19240061","title":"Coeliac disease-associated risk variants in TNFAIP3 and REL implicate altered NF-kappaB signalling.","date":"2009","source":"Gut","url":"https://pubmed.ncbi.nlm.nih.gov/19240061","citation_count":157,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"20186120","id":"PMC_20186120","title":"A functional peptidyl-tRNA hydrolase, ICT1, has been recruited into the human mitochondrial ribosome.","date":"2010","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/20186120","citation_count":153,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"31995728","id":"PMC_31995728","title":"AMPK, a Regulator of Metabolism and Autophagy, Is Activated by Lysosomal Damage via a Novel Galectin-Directed Ubiquitin Signal Transduction System.","date":"2020","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/31995728","citation_count":152,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8514800","id":"PMC_8514800","title":"The mitochondrial tricarboxylate transport protein. cDNA cloning, primary structure, and comparison with other mitochondrial transport proteins.","date":"1993","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8514800","citation_count":143,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"31871319","id":"PMC_31871319","title":"Mapping the proximity interaction network of the Rho-family GTPases reveals signalling pathways and regulatory mechanisms.","date":"2019","source":"Nature cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/31871319","citation_count":137,"is_preprint":false,"source_track":"gene2pubmed"}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":47436,"output_tokens":3506,"usd":0.097449},"stage2":{"model":"claude-opus-4-6","input_tokens":6922,"output_tokens":3241,"usd":0.173453},"total_usd":0.59701,"stage1_batch_id":"msgbatch_011rkcQdVV1RaFq9XhcG6df6","stage2_batch_id":"msgbatch_01RzgrJafdF4EWHhj5mNi6dh","note":"batch pricing = 50% of standard","round2_stage1":{"model":"claude-sonnet-4-6","input_tokens":59535,"output_tokens":5927,"usd":0.133755},"round2_rules_fired":"R2","round2_stage2":{"model":"claude-opus-4-6","input_tokens":9372,"output_tokens":3255,"usd":0.192353}},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2009,\n      \"finding\": \"SLC25A1 (Sea/CIC in Drosophila) transports citrate from mitochondria to the cytosol; loss of function via mutations or siRNA knockdown impairs citrate transport, causing extensive chromosome breakage in mitotic cells, an ATR-dependent cell cycle arrest, and a dramatic reduction in global histone acetylation, establishing a conserved role for SLC25A1 in maintaining chromosome integrity through citrate-dependent histone acetylation.\",\n      \"method\": \"Drosophila sea mutants, siRNA knockdown in human primary fibroblasts, cytogenetic analysis, histone acetylation assays\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — replicated across two organisms (Drosophila and human fibroblasts) with orthogonal methods including genetic mutants, siRNA KD, chromosome analysis, and histone acetylation measurements\",\n      \"pmids\": [\"19654186\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Recessive loss-of-function mutations in SLC25A1 cause combined D-2- and L-2-hydroxyglutaric aciduria; stable isotope labeling experiments and absence of SLC25A1 protein in patient fibroblasts demonstrated impaired mitochondrial citrate efflux as the pathogenic mechanism.\",\n      \"method\": \"Exome sequencing, stable isotope labeling in patient fibroblasts, Western blot confirming absence of SLC25A1 protein\",\n      \"journal\": \"American journal of human genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (genetic, metabolic labeling, protein expression) in patient-derived cells; strong mechanistic link between citrate efflux deficiency and disease\",\n      \"pmids\": [\"23561848\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"SLC25A1 (CIC) is transcriptionally induced by TNFα and IFNγ via NF-κB and STAT1 transcription factors; the citrate exported from mitochondria via SLC25A1 and its downstream metabolite acetyl-CoA are required for cytokine-induced nitric oxide and prostaglandin production, placing SLC25A1 as a central regulator of inflammatory signaling.\",\n      \"method\": \"siRNA knockdown of SLC25A1, cytokine stimulation assays (TNFα, IFNγ), measurement of nitric oxide and prostaglandin levels, promoter/transcription factor analysis\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — loss-of-function with defined cellular phenotype, multiple inflammatory readouts, pathway placement via NF-κB and STAT1\",\n      \"pmids\": [\"25072865\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Mutations in SLC25A1 cause impaired citrate carrier function as demonstrated by in vitro mutant protein functional assay, and SLC25A1 knockdown in zebrafish mirrors human disease with neuromuscular junction abnormalities, implicating pre-synaptic nerve terminal defects as the mechanism of congenital myasthenic syndrome.\",\n      \"method\": \"Homozygosity mapping, whole exome sequencing, in vitro mutant carrier function assay, zebrafish SLC25A1 knockdown model with NMJ phenotyping\",\n      \"journal\": \"Journal of neuromuscular diseases\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional assay of mutant protein plus animal model with defined NMJ phenotype, but single lab study\",\n      \"pmids\": [\"26870663\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"SLC25A1 maintains the mitochondrial pool of citrate and redox balance in lung cancer stem cells (CSCs); its inhibition leads to reactive oxygen species accumulation and inhibits CSC self-renewal. Resistance to cisplatin or EGFR inhibitors is acquired through SLC25A1-mediated enhancement of mitochondrial activity and induction of stemness, and pharmacological inhibition of SLC25A1 is synthetic lethal with these agents.\",\n      \"method\": \"SLC25A1 inhibitor (CTPI-2), CSC self-renewal assays, ROS measurements, metabolic profiling, in vitro and in vivo (animal model) drug combination experiments\",\n      \"journal\": \"Cell death and differentiation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (pharmacological inhibition, metabolic assays, in vivo models) with defined mechanistic readouts in a single rigorous study\",\n      \"pmids\": [\"29651165\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Pharmacological inhibition of Slc25a1 with CTPI-2 or liver-targeted knockout reverses steatosis, reduces inflammatory macrophage infiltration, blunts PPARγ signaling, inhibits gluconeogenic gene expression, and normalizes hyperglycemia, demonstrating that Slc25a1 acts through citrate-dependent lipogenic and metabolic programs in NAFLD/NASH pathogenesis.\",\n      \"method\": \"Slc25a1-specific inhibitor (CTPI-2), global heterozygous knockout, liver-targeted conditional knockout, metabolic phenotyping, gene expression analysis, in vivo NAFLD/NASH mouse models\",\n      \"journal\": \"Cell death and differentiation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple genetic and pharmacological approaches with mechanistic pathway placement (PPARγ, gluconeogenesis) and strong phenotypic readouts\",\n      \"pmids\": [\"31959914\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"SLC25A1 supports cellular and mitochondrial redox homeostasis and metabolic flexibility in cancer cells under hypoxia/reoxygenation stress; pharmacological inhibition disturbs redox balance, lowers mitochondrial metabolism, and sensitizes cells to ionizing radiation by increasing ROS and reducing DNA repair capacity.\",\n      \"method\": \"SLC25A1 inhibitors (BTA, CNASB), ROS measurements, mitochondrial respiration assays, clonogenic survival assays after irradiation, in vitro cell models\",\n      \"journal\": \"Frontiers in oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — pharmacological inhibition with multiple orthogonal mechanistic readouts, but single lab and no genetic validation\",\n      \"pmids\": [\"29888201\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"SLC25A1 drives de novo lipid synthesis under normal conditions and promotes oxidative phosphorylation under metabolic stress in colorectal cancer cells; SLC25A1 knockdown inhibits G1/S cell cycle progression and induces apoptosis, while overexpression suppresses the malignant phenotype, demonstrating its role in energy metabolism reprogramming.\",\n      \"method\": \"siRNA knockdown, SLC25A1 overexpression, cell cycle analysis, apoptosis assays, xenograft in vivo model, metabolic assays\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — bidirectional manipulation (KD and OE) with defined phenotypic and metabolic readouts, but single lab\",\n      \"pmids\": [\"34839347\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"SLC25A1 overexpression in mouse forebrain neurons increases steady-state cytosolic citrate and acetyl-CoA levels and produces autistic-like behaviors with altered synaptic morphology, disrupted white matter integrity, and activated microglia, demonstrating that SLC25A1-mediated citrate export sustains the cytosolic acetyl-CoA pool required for normal neuronal function.\",\n      \"method\": \"Neuron-specific SLC25A1 transgenic mouse, behavioral testing, metabolomics (citrate and acetyl-CoA measurement), proteomic and acetyl-proteomic analysis, histology\",\n      \"journal\": \"Brain : a journal of neurology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — transgenic animal model with multiple orthogonal readouts (metabolomics, proteomics, behavior, histology) establishing mechanistic link between SLC25A1 activity and neuronal phenotype\",\n      \"pmids\": [\"35203088\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"IL-1β stimulation induces IRAKM Myddosome translocation to mitochondria, where IRAKM interacts with and phosphorylates SLC25A1 (Slc25a1) to promote mitochondrial citrate export to the cytosol, thereby driving de novo lipogenesis and adipocyte hypertrophy; IRAKM also mediates IL-1β-induced PGC1α acetylation via this axis.\",\n      \"method\": \"Adipocyte-specific IRAKM knockout mice, co-immunoprecipitation, phosphorylation assays, mitochondrial citrate transport measurements, lipogenesis assays, in vivo HFD model\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — reconstitution of IRAKM-Slc25a1 interaction by Co-IP and phosphorylation assays, supported by genetic KO model with defined metabolic phenotype\",\n      \"pmids\": [\"35585086\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"KRASG12D upregulates SLC25A1 transcription via GLI1, which directly binds the SLC25A1 promoter; enhanced SLC25A1 expression increases cytosolic citrate and fatty acids, promoting lipid metabolism reprogramming in pancreatic cancer; pharmacological inhibition of SLC25A1 or GLI1 suppresses pancreatic tumorigenesis in vivo.\",\n      \"method\": \"Genetically engineered mouse models, ChIP of GLI1 on SLC25A1 promoter, SLC25A1 inhibitor treatment, metabolic profiling, in vivo tumor suppression studies\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — direct promoter binding established by ChIP, supported by animal models and pharmacological validation\",\n      \"pmids\": [\"37695315\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"SLC25A1 exports citrate from mitochondria to the cytosol, where ACLY converts it to acetyl-CoA; this acetyl-CoA sustains FSP1 acetylation at K168 (by KAT2B) which prevents K29-linked ubiquitin-mediated proteasomal degradation of FSP1, thereby suppressing ferroptosis; pharmacological inhibition of SLC25A1 or ACLY enhances ferroptosis susceptibility in cancer cells in vitro and in vivo.\",\n      \"method\": \"CRISPR-Cas9 SLC superfamily screen, SLC25A1/ACLY inhibitors, acetylation and ubiquitination mapping (K168 site), FSP1 stability assays, in vivo tumor models\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — CRISPR screen followed by mechanistic dissection including site mapping, PTM identification (acetylation writer KAT2B, deacetylase HDAC3, ubiquitin linkage K29), and in vivo validation\",\n      \"pmids\": [\"39881208\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"SLC25A1 systemic overexpression in mice increases cytosolic citrate and acetyl-CoA but does not engage ER acetylation machinery (SLC33A1) or cause premature aging, in contrast to SLC13A5 overexpression, demonstrating that the directionality and source of cytosolic citrate transduction produce distinct biological responses.\",\n      \"method\": \"Systemic transgenic mouse models for SLC25A1 and SLC13A5, metabolomic profiling, comparison of ER acetylation pathway engagement\",\n      \"journal\": \"Communications biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — comparative transgenic animal model with metabolomics, moderate evidence due to single lab\",\n      \"pmids\": [\"37689798\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"SLC25A1 encodes the mitochondrial citrate carrier located in the inner mitochondrial membrane that exports citrate (in exchange for malate) from the mitochondrial matrix to the cytosol, where citrate is converted by ATP citrate lyase (ACLY) to acetyl-CoA and oxaloacetate; this citrate/acetyl-CoA axis regulates de novo lipogenesis, histone acetylation and chromosome integrity, inflammatory mediator production (nitric oxide, prostaglandins) downstream of NF-κB/STAT1, ferroptosis resistance via FSP1 acetylation, and mitochondrial redox balance in cancer stem cells, while its activity can be post-translationally modulated by IRAKM-mediated phosphorylation and transcriptionally regulated by GLI1 downstream of oncogenic KRAS.\"\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\nI'll systematically classify each paper, then extract discoveries only from KEPT papers about SLC25A1 (the mitochondrial citrate carrier).\n\n**Classification:**\n- Papers about SLC25A1/CIC (citrate carrier): KEEP — [6], [11], [12], [14], [24], [26], [38], [40], [69], [71], [75], [78], [81], [83], [88], [90], [95], [100]\n- Papers about CIC (capicua transcriptional repressor gene): EXCLUDE (alias collision)\n- Papers about CTP synthase/cytidylyltransferases: EXCLUDE (different genes)\n- Papers about ClC chloride channels: EXCLUDE\n- Papers about ParB/CTP switches in bacteria: EXCLUDE\n- General proteomics/interactome papers mentioning SLC25A1 incidentally: generally EXCLUDE unless mechanistic\n- PMID:23266187 (Palmieri SLC25 family review): KEEP — describes SLC25A1 transport mechanism\n- PMID:8514800 (tricarboxylate transport protein cloning): KEEP — foundational structure/function\n- PMID:21787310 (mitochondrial citrate carrier in inflammation): KEEP\n- PMID:19654186 (Drosophila sea/SLC25A1 chromosome integrity): KEEP\n- PMID:35203088 (SLC25A1 overexpression autism-like phenotype): KEEP\n\n```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1993,\n      \"finding\": \"The rat liver mitochondrial tricarboxylate transport protein (SLC25A1 ortholog) was cloned and its primary structure determined. The protein is 298 amino acids (mature form) with a 13-residue presequence, contains three related ~100-amino-acid sequence domains each with two predicted transmembrane α-helices (six total), placing it in the mitochondrial carrier family with a characteristic tripartite topology.\",\n      \"method\": \"cDNA cloning via PCR with primers from direct protein sequencing; hydrophobicity analysis; Southern blot\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct sequencing of purified protein combined with cDNA cloning; foundational structural characterization\",\n      \"pmids\": [\"8514800\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Mutations in the Drosophila ortholog of SLC25A1 (scheggia/sea) impair citrate transport from mitochondria to cytosol, causing extensive chromosome breakage in mitotic cells, ATR-dependent cell cycle arrest, and a dramatic reduction in global histone acetylation. Loss of SLC25A1 by siRNA in human primary fibroblasts similarly leads to chromosome breaks and histone acetylation defects, establishing an evolutionarily conserved role for SLC25A1 in supplying cytosolic citrate (and downstream acetyl-CoA) for chromatin acetylation and genome stability.\",\n      \"method\": \"Drosophila genetics (sea mutants), siRNA knockdown in human fibroblasts, chromosome breakage assays, ATR pathway analysis, global histone acetylation measurement\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — orthogonal genetic and biochemical approaches in two organisms with defined cellular phenotypes\",\n      \"pmids\": [\"19654186\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"The mitochondrial citrate carrier (CIC/SLC25A1) is induced at the mRNA and protein level by lipopolysaccharide in immune cells. Gene silencing or pharmacological inhibition of CIC significantly reduces production of nitric oxide, reactive oxygen species, and prostaglandins in activated macrophages, demonstrating that CIC-mediated citrate export is required for the generation of inflammatory mediators.\",\n      \"method\": \"LPS stimulation, CIC gene silencing (siRNA), CIC activity inhibition, NO/ROS/prostaglandin assays\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal loss-of-function approaches (siRNA and inhibitor) with specific biochemical readouts, replicated across conditions\",\n      \"pmids\": [\"21787310\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"SLC25A1 is a member of the mitochondrial carrier superfamily (SLC25) characterized by a tripartite structure, six transmembrane α-helices, and 3-fold repeated signature motifs embedded in the inner mitochondrial membrane. It functions as an antiporter exchanging citrate (and isocitrate) efflux from the mitochondrial matrix for cytosolic malate import.\",\n      \"method\": \"Comparative sequence analysis, heterologous expression, reconstitution into liposomes, transport assays\",\n      \"journal\": \"Molecular aspects of medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstitution in liposomes with transport assays; consistent with broader SLC25 family characterization\",\n      \"pmids\": [\"23266187\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Recessive loss-of-function mutations in SLC25A1 cause combined D-2- and L-2-hydroxyglutaric aciduria. Stable isotope labeling experiments in patient fibroblasts demonstrated impaired mitochondrial citrate efflux, and absence of SLC25A1 protein was shown in fibroblasts with certain mutations, establishing that SLC25A1 deficiency is the pathogenic mechanism underlying this neurometabolic disease.\",\n      \"method\": \"Whole exome sequencing, stable isotope labeling experiments in patient fibroblasts, immunoblotting for SLC25A1 protein\",\n      \"journal\": \"American journal of human genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — functional impairment demonstrated by isotope labeling in patient cells; 12/12 individuals with this disease had SLC25A1 mutations\",\n      \"pmids\": [\"23561848\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"SLC25A1 is transcriptionally induced by TNFα and IFNγ via NF-κB and STAT1 transcription factors. The citrate exported from mitochondria via SLC25A1, and its downstream metabolic intermediate acetyl-CoA, are necessary for cytokine-induced nitric oxide and prostaglandin production, placing SLC25A1-mediated citrate export as a central node in the inflammatory metabolic pathway.\",\n      \"method\": \"Cytokine stimulation, transcription factor inhibition (NF-κB, STAT1), SLC25A1 knockdown, metabolite measurements (citrate, acetyl-CoA, NO, prostaglandins)\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal approaches linking transcriptional regulation to metabolic output with specific pathway placement\",\n      \"pmids\": [\"25072865\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"A homozygous missense mutation in SLC25A1 causes impaired neuromuscular junction (NMJ) function in addition to metabolic disease. Mutant SLC25A1 protein showed abnormal carrier function in vitro. Knockdown of SLC25A1 in zebrafish recapitulated the human disease phenotype with clear NMJ abnormalities and axonal outgrowth defects, suggesting the NMJ impairment is related to pre-synaptic nerve terminal defects secondary to mitochondrial citrate transport dysfunction.\",\n      \"method\": \"Whole exome sequencing, in vitro mutant carrier function assay, zebrafish SLC25A1 knockdown, NMJ morphology analysis\",\n      \"journal\": \"Journal of neuromuscular diseases\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vitro functional assay plus zebrafish model; single lab study\",\n      \"pmids\": [\"26870663\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"SLC25A1 deficiency (combined D,L-2-hydroxyglutaric aciduria) leads to depletion of cytosolic citrate and accumulation of intramitochondrial citrate. Citrate supplementation (but not malate) in a patient reduced urinary D2HG and L2HG levels and stabilized seizure frequency, consistent with the model that impaired SLC25A1-mediated citrate export drives accumulation of 2-hydroxyglutarate species.\",\n      \"method\": \"Clinical metabolite monitoring (organic acid profiling), citrate vs. malate treatment intervention in a patient\",\n      \"journal\": \"Journal of inherited metabolic disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — single patient clinical intervention providing mechanistic insight; consistent with established transport function\",\n      \"pmids\": [\"24687295\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Severe neonatal SLC25A1 deficiency (homozygous p.Arg198His, within the putative substrate-binding site I of the carrier) results in lactic acidosis, reduced mitochondrial spare respiratory capacity, and increased glycolytic flux in patient fibroblasts, demonstrating that loss of mitochondrial citrate export impairs mitochondrial bioenergetics and forces metabolic reprogramming toward glycolysis.\",\n      \"method\": \"Exome sequencing, Seahorse respirometry in patient fibroblasts, mitochondrial membrane potential assays, citrate supplementation rescue experiments\",\n      \"journal\": \"JIMD reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional bioenergetics assays in patient fibroblasts; single case but with multiple orthogonal measurements\",\n      \"pmids\": [\"27306203\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"SLC25A1 is upregulated in lung cancer stem cells (CSCs) and by hypoxia/reoxygenation stress and ionizing radiation. SLC25A1 maintains the mitochondrial pool of citrate and redox balance in CSCs; its inhibition (using BTA or CNASB) leads to reactive oxygen species accumulation, reduced mitochondrial metabolism, impaired DNA repair capacity, and inhibition of CSC self-renewal. SLC25A1 inhibition is synthetic lethal with cisplatin or EGFR inhibitor treatment.\",\n      \"method\": \"SLC25A1 inhibition with BTA/CNASB, CSC sphere assays, ROS measurement, clonogenic survival, xenograft models, metabolic profiling\",\n      \"journal\": \"Cell death and differentiation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal functional assays in vitro and in vivo animal models; replicated with two distinct inhibitors\",\n      \"pmids\": [\"29651165\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"SLC25A1 upregulation by hypoxia/reoxygenation stress supports cellular and mitochondrial redox homeostasis and metabolic flexibility in cancer cells. Pharmacological inhibition of SLC25A1 disturbs redox balance, lowers mitochondrial metabolism, and radiosensitizes cancer cells by increasing ROS and reducing DNA repair capacity, particularly in chronically hypoxic tumor cells.\",\n      \"method\": \"SLC25A1 inhibition (BTA, CNASB), irradiation clonogenic assays, ROS measurement, DNA damage (γH2AX) assays, metabolic flux analysis in multiple cancer cell lines\",\n      \"journal\": \"Frontiers in oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple cell lines and inhibitors with mechanistic endpoint measurements; single lab\",\n      \"pmids\": [\"29888201\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"ADGRL4/ELTD1 silencing in endothelial cells induces transcriptional upregulation of SLC25A1 (and ACLY), altering the cellular metabolic profile. Affected metabolites include elevated cis-aconitic acid and depleted cytidine monophosphate, suggesting SLC25A1 participates in a metabolic regulatory circuit downstream of ADGRL4/ELTD1 in endothelial cells.\",\n      \"method\": \"siRNA silencing of ADGRL4/ELTD1 in HUVECs, transcriptional profiling, LC-MS metabolomics\",\n      \"journal\": \"Metabolites\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — SLC25A1 upregulation is a downstream consequence; no direct functional manipulation of SLC25A1 itself\",\n      \"pmids\": [\"31775252\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Pharmacological inhibition of Slc25a1 with CTPI-2 in mouse models of NAFLD/NASH reverts steatosis, reduces inflammatory macrophage infiltration, mitigates obesity, and normalizes hyperglycemia. Mechanistically, Slc25a1 inhibition rewires the lipogenic program by blunting PPARγ signaling and inhibiting gluconeogenic gene expression via citrate-dependent activities. Liver-targeted Slc25a1 knockout recapitulates metabolic improvements, demonstrating tissue-specific functions.\",\n      \"method\": \"CTPI-2 pharmacological inhibition, global Slc25a1 heterozygous knockout, liver-targeted conditional Slc25a1 knockout, high-fat diet NASH model, lipid profiling, glucose tolerance tests, PPARγ and gluconeogenic gene expression analysis\",\n      \"journal\": \"Cell death and differentiation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple genetic and pharmacological approaches in vivo with specific mechanistic pathway placement\",\n      \"pmids\": [\"31959914\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"SLC25A1 knockdown in colorectal cancer cells inhibits G1/S cell cycle progression and induces apoptosis. SLC25A1 reprograms energy metabolism by: (1) increasing de novo lipid synthesis under normal conditions, and (2) increasing oxidative phosphorylation to protect against energy stress-induced apoptosis, demonstrating dual metabolic roles dependent on nutritional context.\",\n      \"method\": \"SLC25A1 knockdown and overexpression in CRC cells, cell cycle analysis, apoptosis assays, OXPHOS measurement, de novo lipogenesis assays, xenograft models\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — bidirectional manipulation (KD and OE) with multiple metabolic readouts; single lab\",\n      \"pmids\": [\"34839347\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Neuronal overexpression of SLC25A1 in mouse forebrain neurons increases steady-state levels of citrate and acetyl-CoA, produces an autistic-like behavioral phenotype with jumping stereotypy, disrupts white matter integrity with activated microglia, and alters synaptic plasticity and morphology. Quantitative acetyl-proteomic analysis reveals differential acetylation adaptations in hippocampus and cortex, linking SLC25A1-mediated citrate export to cytosolic acetyl-CoA availability and downstream protein acetylation in neurons.\",\n      \"method\": \"Transgenic mouse overexpression of SLC25A1 in forebrain neurons, behavioral testing, metabolomics (citrate, acetyl-CoA), MRI white matter integrity, electrophysiology, quantitative proteomics and acetyl-proteomics\",\n      \"journal\": \"Brain : a journal of neurology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — transgenic mouse model with multiple orthogonal biochemical, imaging, behavioral, and proteomic endpoints\",\n      \"pmids\": [\"35203088\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"IL-1β stimulation induces translocation of IRAKM Myddosome to mitochondria, where IRAKM interacts with and phosphorylates the mitochondrial citrate carrier Slc25a1. This phosphorylation promotes IL-1β-induced mitochondrial citrate transport to the cytosol and drives de novo lipogenesis in adipocytes. The IRAKM-Slc25a1 axis also mediates IL-1β-induced PGC1α acetylation to regulate thermogenic gene expression. Adipocyte-specific IRAKM deficiency reduces high-fat diet-induced obesity.\",\n      \"method\": \"Co-immunoprecipitation of IRAKM with Slc25a1, kinase phosphorylation assays, adipocyte-specific IRAKM knockout mice, HFD obesity model, mitochondrial citrate transport assay, de novo lipogenesis measurement, acetylation assays\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — direct biochemical interaction (Co-IP), kinase assay, and in vivo genetic model with specific metabolic readouts\",\n      \"pmids\": [\"35585086\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"KRASG12D upregulates SLC25A1 expression in pancreatic cancer via GLI1, which directly binds the SLC25A1 promoter to stimulate its transcription. Enhanced SLC25A1 expression increases cytosolic citrate, fatty acids, and key lipid metabolism enzymes. A high-fat diet further stimulates the KRASG12D-GLI1-SLC25A1 axis. Pharmacological inhibition of SLC25A1 or GLI1 significantly suppresses pancreatic tumorigenesis in KrasG12D/+ mice.\",\n      \"method\": \"ChIP demonstrating GLI1 binding to SLC25A1 promoter, genetically engineered KrasG12D mouse models, SLC25A1/GLI1 pharmacological inhibition, metabolomics (citrate, fatty acids), HFD tumor models\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — ChIP for direct transcriptional regulation, in vivo mouse model, multiple orthogonal metabolic measurements\",\n      \"pmids\": [\"37695315\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Systemic overexpression of SLC25A1 in mice increases cytosolic citrate and acetyl-CoA but does not engage the ER acetylation machinery (SLC33A1) or cause premature death (unlike SLC13A5 overexpression), revealing that the directionality of citrate import (mitochondrial export via SLC25A1 vs. extracellular import via SLC13A5) produces fundamentally different biological responses and metabolic profiles despite both elevating cytosolic citrate.\",\n      \"method\": \"Transgenic mice with systemic SLC25A1 overexpression, comparative metabolomics with SLC13A5 transgenic mice, ER acetylation machinery analysis, phenotypic characterization\",\n      \"journal\": \"Communications biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct comparison of transgenic models with metabolomics; demonstrates source-specific citrate signaling\",\n      \"pmids\": [\"37689798\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"SLC25A1 exports citrate from mitochondria to the cytosol, where ATP citrate lyase (ACLY) converts it to acetyl-CoA. This cytosolic acetyl-CoA sustains FSP1 acetylation at K168 (mediated by KAT2B and reversed by HDAC3), preventing FSP1 degradation via K29-linked ubiquitin chains and thus protecting cancer cells from ferroptosis. Pharmacological inhibition of SLC25A1 reduces FSP1 acetylation, promotes its proteasomal degradation, and enhances ferroptosis sensitivity both in vitro and in vivo.\",\n      \"method\": \"CRISPR-Cas9 screen of SLC superfamily, SLC25A1 inhibition (CTPI-2), ACLY inhibition, FSP1 acetylation and ubiquitination assays, site-directed mutagenesis (K168), KAT2B/HDAC3 identification, ferroptosis assays in vitro and xenograft models\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — CRISPR screen, reconstitution of acetylation pathway, mutagenesis of key sites, in vivo validation; multiple orthogonal methods\",\n      \"pmids\": [\"39881208\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Parthenolide (PTL) inhibits SLC25A1 expression, causing ROS production, reduced oxidative phosphorylation, and mitochondrial dysfunction in liver cancer stem cells. SLC25A1 inhibition also decreases IDH2 expression and mitochondrial respiratory chain complex genes. The inhibitory effects of PTL on mitochondrial function and self-renewal are abolished by SLC25A1 knockdown or CTPI-2 treatment, demonstrating that PTL acts through SLC25A1-mediated mitochondrial function.\",\n      \"method\": \"RNA-seq, SLC25A1 knockdown, CTPI-2 inhibitor, ROS assay, OXPHOS measurement, mitochondrial membrane potential, sphere formation assays, in vivo xenograft\",\n      \"journal\": \"Cell death discovery\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple approaches but PTL has pleiotropic effects; SLC25A1 specificity established by genetic knockdown corroborating inhibitor\",\n      \"pmids\": [\"37741815\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"SLC25A1 (mitochondrial citrate carrier/CIC) is an inner mitochondrial membrane antiporter with a tripartite six-transmembrane-helix structure that exports citrate (and isocitrate) from the mitochondrial matrix in exchange for cytosolic malate; this citrate export fuels cytosolic acetyl-CoA production via ACLY, thereby regulating de novo lipogenesis, histone acetylation and chromatin integrity, ferroptosis resistance (via FSP1 acetylation), inflammatory mediator production (NO, prostaglandins) downstream of NF-κB/STAT1 and IL-1R-IRAKM signaling, cancer stem cell redox balance, and glucose/lipid homeostasis in liver and adipose tissue, while loss-of-function mutations cause combined D,L-2-hydroxyglutaric aciduria with neurometabolic disease.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"SLC25A1 is the mitochondrial citrate carrier that exports citrate from the mitochondrial matrix to the cytosol in exchange for malate, thereby fueling cytosolic acetyl-CoA production and linking mitochondrial metabolism to lipogenesis, histone acetylation, inflammatory mediator synthesis, and ferroptosis resistance. Cytosolic citrate exported by SLC25A1 is converted by ATP citrate lyase (ACLY) to acetyl-CoA, which sustains global histone acetylation required for chromosome integrity, drives de novo lipid synthesis in cancer and metabolic disease, and maintains FSP1 protein stability through KAT2B-mediated acetylation to suppress ferroptosis [PMID:19654186, PMID:39881208, PMID:34839347]. SLC25A1 is transcriptionally induced by NF-κB/STAT1 during inflammation and by GLI1 downstream of oncogenic KRAS, and its activity is post-translationally enhanced by IRAKM-mediated phosphorylation at the mitochondrial surface [PMID:25072865, PMID:37695315, PMID:35585086]. Recessive loss-of-function mutations in SLC25A1 cause combined D-2- and L-2-hydroxyglutaric aciduria with impaired mitochondrial citrate efflux [PMID:23561848].\",\n  \"teleology\": [\n    {\n      \"year\": 2009,\n      \"claim\": \"Establishing that SLC25A1-mediated citrate export is required for histone acetylation and chromosome stability resolved how a mitochondrial transporter could influence nuclear chromatin integrity.\",\n      \"evidence\": \"Drosophila sea mutants and siRNA knockdown in human fibroblasts, with cytogenetic analysis and histone acetylation assays\",\n      \"pmids\": [\"19654186\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"The specific histone marks and acetyltransferases downstream of SLC25A1-derived acetyl-CoA were not identified\",\n        \"Whether the chromosome breakage phenotype is reversible by citrate supplementation was not tested in human cells\"\n      ]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Identification of recessive SLC25A1 mutations as the cause of combined D-2- and L-2-hydroxyglutaric aciduria demonstrated a direct metabolic disease consequence of impaired mitochondrial citrate efflux.\",\n      \"evidence\": \"Exome sequencing, stable isotope labeling in patient fibroblasts, Western blot confirming absence of SLC25A1 protein\",\n      \"pmids\": [\"23561848\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"The biochemical mechanism linking citrate efflux loss to hydroxyglutaric acid accumulation was not fully delineated\",\n        \"Whether residual carrier activity from hypomorphic alleles modulates disease severity was not tested\"\n      ]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Demonstrating that NF-κB and STAT1 transcriptionally induce SLC25A1 and that its citrate export is required for nitric oxide and prostaglandin production placed the carrier as a metabolic node in innate inflammatory signaling.\",\n      \"evidence\": \"siRNA knockdown, TNFα/IFNγ stimulation, measurement of NO and prostaglandin levels, promoter analysis\",\n      \"pmids\": [\"25072865\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Whether SLC25A1-derived acetyl-CoA feeds into prostaglandin synthesis via acetylation of biosynthetic enzymes or via lipid precursor supply was not resolved\",\n        \"The contribution of SLC25A1 to inflammatory signaling in primary macrophages in vivo was not tested\"\n      ]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Functional assay of disease-associated SLC25A1 mutants and zebrafish knockdown revealed that impaired citrate carrier activity causes neuromuscular junction defects, extending the disease spectrum to congenital myasthenic syndrome.\",\n      \"evidence\": \"In vitro mutant carrier function assay, zebrafish SLC25A1 knockdown with NMJ phenotyping\",\n      \"pmids\": [\"26870663\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Single-lab study without independent replication of the NMJ phenotype\",\n        \"Whether citrate supplementation rescues the NMJ defect was not tested\",\n        \"The specific presynaptic metabolic pathway disrupted at the NMJ was not identified\"\n      ]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Pharmacological and genetic studies in cancer cells established that SLC25A1 maintains mitochondrial redox balance, supports cancer stem cell self-renewal, and that its inhibition is synthetic lethal with cisplatin or radiation, revealing SLC25A1 as a therapeutic vulnerability.\",\n      \"evidence\": \"SLC25A1 inhibitors (CTPI-2, BTA, CNASB), CSC self-renewal assays, ROS measurements, clonogenic survival after irradiation, in vivo tumor models\",\n      \"pmids\": [\"29651165\", \"29888201\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"No genetic validation (knockout/knockdown) was performed in the radiation sensitization study\",\n        \"Whether the synthetic lethality generalizes across tumor types beyond lung cancer was not established\"\n      ]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Liver-targeted knockout and pharmacological inhibition of Slc25a1 reversed steatosis and hyperglycemia in NAFLD/NASH models, demonstrating that its citrate export drives pathogenic lipogenic and gluconeogenic programs in vivo.\",\n      \"evidence\": \"Slc25a1 conditional liver knockout, heterozygous global knockout, CTPI-2 treatment, metabolic phenotyping in NAFLD/NASH mouse models\",\n      \"pmids\": [\"31959914\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Whether long-term SLC25A1 inhibition produces metabolic side effects in non-hepatic tissues was not assessed\",\n        \"The relative contribution of PPARγ signaling versus direct lipogenic enzyme supply to the steatosis phenotype was not dissected\"\n      ]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Bidirectional manipulation of SLC25A1 in colorectal cancer showed it drives de novo lipogenesis under basal conditions and switches to supporting oxidative phosphorylation under metabolic stress, revealing a metabolic flexibility role.\",\n      \"evidence\": \"siRNA knockdown and overexpression in colorectal cancer cells, cell cycle analysis, apoptosis assays, xenograft model, metabolic assays\",\n      \"pmids\": [\"34839347\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Single-lab study\",\n        \"The molecular sensor or switch governing the lipogenesis-to-OXPHOS transition was not identified\"\n      ]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Neuron-specific SLC25A1 overexpression demonstrated that elevated mitochondrial citrate export raises cytosolic acetyl-CoA, disrupts synaptic morphology and white matter integrity, and produces autistic-like behaviors, establishing a direct link between SLC25A1 activity and neuronal function.\",\n      \"evidence\": \"Neuron-specific transgenic mouse, behavioral testing, metabolomics, acetyl-proteomics, histology\",\n      \"pmids\": [\"35203088\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Whether the behavioral phenotype is reversible upon SLC25A1 normalization was not tested\",\n        \"Specific acetylated neuronal substrates mediating the synaptic and behavioral phenotype were not identified\"\n      ]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Discovery that IRAKM translocates to mitochondria and phosphorylates SLC25A1 to enhance citrate export upon IL-1β stimulation revealed a direct post-translational activation mechanism linking innate immune signaling to lipogenesis and adipocyte hypertrophy.\",\n      \"evidence\": \"Adipocyte-specific IRAKM knockout mice, co-immunoprecipitation, phosphorylation assays, mitochondrial citrate transport measurements, in vivo HFD model\",\n      \"pmids\": [\"35585086\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"The specific phosphorylation site(s) on SLC25A1 were not mapped\",\n        \"Whether other kinases similarly regulate SLC25A1 transport activity was not explored\"\n      ]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"ChIP-validated binding of GLI1 to the SLC25A1 promoter downstream of KRAS^G12D defined a transcriptional axis by which oncogenic KRAS reprograms lipid metabolism in pancreatic cancer via SLC25A1 upregulation.\",\n      \"evidence\": \"Genetically engineered KRAS mouse models, ChIP of GLI1 on SLC25A1 promoter, SLC25A1/GLI1 inhibitor treatment, in vivo tumor suppression\",\n      \"pmids\": [\"37695315\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Whether other oncogenic drivers converge on GLI1-SLC25A1 transcription was not tested\",\n        \"The relative contribution of SLC25A1 versus other GLI1 targets to KRAS-driven tumorigenesis was not quantified\"\n      ]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"A CRISPR screen and mechanistic dissection established that SLC25A1-derived citrate, via ACLY-generated acetyl-CoA, sustains KAT2B-mediated acetylation of FSP1 at K168, preventing K29-linked ubiquitination and proteasomal degradation, thereby suppressing ferroptosis — connecting the citrate carrier to a specific anti-ferroptotic PTM cascade.\",\n      \"evidence\": \"CRISPR-Cas9 SLC superfamily screen, SLC25A1/ACLY inhibitors, acetylation and ubiquitination site mapping, FSP1 stability assays, in vivo tumor models\",\n      \"pmids\": [\"39881208\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Whether SLC25A1-mediated FSP1 stabilization operates in non-cancer cell contexts was not tested\",\n        \"The deacetylase HDAC3 was identified but its regulation in this pathway was not fully characterized\"\n      ]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the precise phosphorylation sites through which IRAKM activates SLC25A1, the structural basis for SLC25A1 citrate/malate exchange, and whether the distinct downstream effects of SLC25A1-derived versus plasma membrane transporter-derived cytosolic citrate reflect compartmentalized acetyl-CoA pools.\",\n      \"evidence\": \"Open question based on current literature\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\n        \"No high-resolution structure of human SLC25A1 in a transport-competent state\",\n        \"IRAKM phosphorylation site(s) on SLC25A1 not mapped\",\n        \"Mechanism by which mitochondrial versus extracellular citrate sources produce distinct biological outcomes remains undefined\"\n      ]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0005215\", \"supporting_discovery_ids\": [0, 1, 4, 5, 8, 9, 11]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005739\", \"supporting_discovery_ids\": [0, 1, 4, 5, 8, 9, 11]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [0, 1, 5, 7, 9, 10, 11]},\n      {\"term_id\": \"R-HSA-382551\", \"supporting_discovery_ids\": [0, 1, 4, 8, 9]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [2, 9]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [7, 11]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [4, 6, 7, 10]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"ACLY\",\n      \"IRAKM\",\n      \"GLI1\",\n      \"FSP1\",\n      \"KAT2B\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"mechanistic_narrative\": \"SLC25A1 is an inner mitochondrial membrane antiporter that exports citrate (and isocitrate) from the mitochondrial matrix in exchange for cytosolic malate, thereby serving as the principal conduit for mitochondrial citrate to reach the cytoplasm where ATP citrate lyase (ACLY) converts it to acetyl-CoA [PMID:8514800, PMID:23266187]. This citrate-to-acetyl-CoA axis supplies substrate for de novo lipogenesis, histone and protein acetylation critical for chromatin integrity and genome stability, and inflammatory mediator synthesis (NO, prostaglandins) downstream of NF-κB/STAT1 signaling in activated macrophages [PMID:19654186, PMID:21787310, PMID:25072865]. SLC25A1-derived acetyl-CoA also sustains FSP1 acetylation to protect cells from ferroptosis, maintains redox homeostasis in cancer stem cells, and is regulated by IRAKM-dependent phosphorylation during IL-1β-driven lipogenesis in adipocytes and by KRAS–GLI1 transcriptional activation in pancreatic cancer [PMID:39881208, PMID:29651165, PMID:35585086, PMID:37695315]. Recessive loss-of-function mutations in SLC25A1 cause combined D,L-2-hydroxyglutaric aciduria, a neurometabolic disorder characterized by impaired mitochondrial citrate efflux, 2-hydroxyglutarate accumulation, and neuromuscular dysfunction [PMID:23561848, PMID:26870663].\",\n  \"teleology\": [\n    {\n      \"year\": 1993,\n      \"claim\": \"Cloning the rat liver tricarboxylate carrier established SLC25A1 as a mitochondrial carrier family member with a tripartite six-transmembrane-helix topology, providing the molecular identity needed for all subsequent functional studies.\",\n      \"evidence\": \"cDNA cloning from direct protein sequencing of purified rat liver carrier; hydrophobicity analysis\",\n      \"pmids\": [\"8514800\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Human orthologue transport kinetics not yet characterized at this stage\", \"No disease association established\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Establishing that SLC25A1-mediated citrate export supplies cytosolic acetyl-CoA for histone acetylation answered why a metabolite transporter is essential for genome stability, linking mitochondrial metabolism to chromatin maintenance.\",\n      \"evidence\": \"Drosophila sea mutant genetics plus siRNA in human fibroblasts; chromosome breakage assays and global histone acetylation measurements\",\n      \"pmids\": [\"19654186\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Specific histone marks affected not resolved\", \"Whether acetyl-CoA depletion or citrate accumulation is the primary driver of breakage was not distinguished\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Demonstrating that SLC25A1 is induced by LPS and required for NO, ROS, and prostaglandin production in macrophages established mitochondrial citrate export as a metabolic bottleneck in innate immune activation.\",\n      \"evidence\": \"siRNA knockdown and pharmacological CIC inhibition in LPS-stimulated macrophages; NO/ROS/prostaglandin quantification\",\n      \"pmids\": [\"21787310\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct metabolic flux measurements of citrate export in immune cells not performed\", \"Relative contribution of citrate versus other mitochondrial metabolites not fully dissected\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Reconstitution of purified SLC25A1 in liposomes confirmed its identity as a citrate/malate antiporter, providing the biochemical gold standard for its transport mechanism.\",\n      \"evidence\": \"Heterologous expression, reconstitution into liposomes, direct transport assays\",\n      \"pmids\": [\"23266187\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"High-resolution structural basis of substrate selectivity not yet available\", \"Regulatory post-translational modifications on the carrier not explored\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Identification of recessive SLC25A1 mutations as the cause of combined D,L-2-hydroxyglutaric aciduria in 12 individuals answered the genetic basis of this neurometabolic disease and confirmed the physiological essentiality of mitochondrial citrate export.\",\n      \"evidence\": \"Whole-exome sequencing of affected families; stable isotope labeling in patient fibroblasts showing impaired citrate efflux\",\n      \"pmids\": [\"23561848\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Precise mechanism linking citrate retention to 2-HG accumulation not fully delineated\", \"Genotype–phenotype correlations across different mutations remain incomplete\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Mapping transcriptional induction of SLC25A1 by TNFα/IFNγ via NF-κB and STAT1 placed the carrier within the inflammatory signaling cascade and identified IRAKM-mediated phosphorylation of SLC25A1 as a direct post-translational activating mechanism during IL-1β signaling in adipocytes.\",\n      \"evidence\": \"Cytokine stimulation with transcription factor inhibition; Co-IP of IRAKM with SLC25A1, kinase assays, adipocyte-specific knockout mice\",\n      \"pmids\": [\"25072865\", \"35585086\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Specific phosphorylation sites on SLC25A1 and their individual functional consequences not fully mapped\", \"Whether phosphorylation alters transport kinetics or carrier stability not distinguished\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Demonstrating NMJ defects in a patient with a homozygous SLC25A1 missense mutation and recapitulation in zebrafish knockdown expanded the disease phenotype beyond metabolic aciduria to include neuromuscular dysfunction.\",\n      \"evidence\": \"Patient exome sequencing, in vitro carrier function assay, zebrafish morpholino knockdown with NMJ morphology analysis\",\n      \"pmids\": [\"26870663\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether NMJ defect is a direct consequence of local citrate depletion or secondary to systemic metabolic imbalance is unclear\", \"Single-family study\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Showing that SLC25A1 is upregulated in cancer stem cells and required for their redox balance, DNA repair, and self-renewal established SLC25A1 as a therapeutic vulnerability, with pharmacological inhibition being synthetic lethal with cisplatin or EGFR blockade.\",\n      \"evidence\": \"BTA and CNASB inhibitors in lung CSC sphere assays, ROS measurement, clonogenic survival, xenograft models\",\n      \"pmids\": [\"29651165\", \"29888201\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Specificity of BTA/CNASB for SLC25A1 versus other mitochondrial carriers not fully established\", \"Patient-derived tumor responses not tested\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Pharmacological and liver-specific genetic ablation of SLC25A1 in NAFLD/NASH mouse models reversed steatosis, obesity, and hyperglycemia by blunting PPARγ-driven lipogenesis and gluconeogenesis, demonstrating tissue-level metabolic functions.\",\n      \"evidence\": \"CTPI-2 treatment, global heterozygous and liver-conditional Slc25a1 knockout mice on high-fat diet; lipid profiling, glucose tolerance tests\",\n      \"pmids\": [\"31959914\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Long-term safety of SLC25A1 inhibition in liver not assessed\", \"Compensatory metabolic pathways upon chronic inhibition not characterized\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Neuronal overexpression of SLC25A1 produced autistic-like behaviors, white matter disruption, and altered synaptic plasticity in mice, with acetyl-proteomics revealing region-specific protein acetylation changes, directly demonstrating that excess mitochondrial citrate export reprograms the neuronal acetylome.\",\n      \"evidence\": \"Forebrain-specific SLC25A1 transgenic mice; behavioral testing, MRI, electrophysiology, quantitative acetyl-proteomics\",\n      \"pmids\": [\"35203088\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Causal link between specific acetylation targets and behavioral phenotype not established\", \"Reversibility of phenotype upon SLC25A1 normalization not tested\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Identification of the KRAS–GLI1–SLC25A1 transcriptional axis in pancreatic cancer revealed how oncogenic signaling co-opts mitochondrial citrate export to fuel lipogenesis and tumorigenesis, and showed that GLI1 directly binds the SLC25A1 promoter.\",\n      \"evidence\": \"ChIP for GLI1 at SLC25A1 promoter, KrasG12D mouse models, pharmacological SLC25A1/GLI1 inhibition, high-fat diet tumor studies\",\n      \"pmids\": [\"37695315\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether GLI1-dependent regulation occurs in non-pancreatic KRAS-driven cancers not tested\", \"Relative contribution of SLC25A1 versus other lipogenic enzymes to KRAS-driven tumor growth not quantified\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Delineation of the SLC25A1→ACLY→acetyl-CoA→KAT2B→FSP1-K168-acetylation pathway established a direct mechanism by which mitochondrial citrate export protects cells from ferroptosis by preventing ubiquitin-dependent FSP1 degradation.\",\n      \"evidence\": \"CRISPR screen of SLC superfamily, CTPI-2 and ACLY inhibitors, FSP1 K168 mutagenesis, KAT2B/HDAC3 identification, in vivo ferroptosis assays\",\n      \"pmids\": [\"39881208\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether this ferroptosis-protective mechanism operates in non-cancer cell types is unknown\", \"Structural basis for KAT2B specificity toward FSP1-K168 not determined\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"A high-resolution structure of human SLC25A1 in distinct conformational states, the full catalog of regulatory phosphorylation sites and their kinases, and the in vivo therapeutic index of SLC25A1 inhibition in cancer and metabolic disease remain to be established.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No atomic-resolution structure of human SLC25A1 reported\", \"Complete post-translational modification map (phosphorylation, acetylation) and their transport-kinetic consequences lacking\", \"Clinical translatability of SLC25A1 inhibitors not assessed in human trials\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0005215\", \"supporting_discovery_ids\": [0, 3, 4]},\n      {\"term_id\": \"GO:0140104\", \"supporting_discovery_ids\": [3, 4]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005739\", \"supporting_discovery_ids\": [0, 3, 4, 8, 15]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [1, 3, 5, 12, 13, 16, 18]},\n      {\"term_id\": \"R-HSA-382551\", \"supporting_discovery_ids\": [0, 3, 4, 7, 8]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [2, 5]},\n      {\"term_id\": \"R-HSA-4839726\", \"supporting_discovery_ids\": [1, 14]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [13, 18]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [4, 6, 9, 16]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"ACLY\",\n      \"IRAKM\",\n      \"GLI1\",\n      \"FSP1\",\n      \"KAT2B\",\n      \"HDAC3\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}